Investigating the importance of PAK1 kinase activity during breast cancer cell spreading and migration by Gale, Madeline Emma
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 

















Investigating the importance of PAK1 kinase activity 
during breast cancer cell spreading and migration 
 
 
















Declaration of Authorship  
I declare that the work presented in this thesis is the work of the author. Contributions 





































When selecting a PhD project, I was advised to consider my choice of supervisor carefully as this 
was as important if not more important than the topic itself. Dr Claire Wells has been motivational, 
encouraging and exceptionally supportive during my time in her lab, and for that I would like to 
express my deepest gratitude to her. There hasn’t been a day when I doubted my choice in 
supervisor. I would like to thank my second supervisor Dr Simon Ameer-Beg for not only his 
patience when teaching me techniques that unfortunately didn’t make it into this thesis, but also 
for his guidance in other aspects of my project. I would like to extend my thanks to the three 
additional members of my thesis committee- Prof. Tony Ng, Dr James Arnold and Dr Fiona Wardle. 
I really appreciate your time, interest and valuable suggestions. 
 
 
To Dr Klaus Hahn and his team, namely Dr Onur Dagliyan, Dr Dan Marston and Orrin Stone- thank 
you for the cells, advice and making my trip to North Carolina one to remember. This thesis would 
be very different if it wasn’t for your collaboration.   
 
 
Some special thanks go to the many Wells’ lab members past and present. Your teachings, 
suggestions and reassurance in the lab were always comforting, and the nights out, coffee 
readings, inappropriate jokes, lunches inside, lunches outside, Christmas parties, snack times and 
so much more have made the last four years a lot of fun. I couldn’t imagine my time in the lab 
without the originals- Dr Katerina Pipili (the best lab Mumma going), Dr Mario De Piano (the avid 
sandwich shaker and vitamin taker), Dr Hoyin Lam (the very important business man who is often 
with a cold) and Dr Kiruthikah Thillai (the only other person in the world who likes to snack as 
much as me and my lab/real life best friend…right?). To later members Dr/Mr Christian Benzing, 
Beth Russell, Noor Jalal, Dr Sevil Oskay and Dr Michaela Lesjak thank you for being equally as 
wonderful and filling in the holes the originals left. To the current members Valeria Manuelli and 
Lujain Kuwair I am sorry for ‘leaving’ you but am hugely thankful for your kindness during the most 
stressful months of my PhD. Valeria, I am so very sorry I won’t be around to see your project unfold, 
teach you to inject fish and watch you settle into your new lab life. Lujain, I will do my best to still 
remind you of all upcoming bank holidays. I am also very grateful to various PhD students and post 
docs on the second floor for their help and friendly faces over the past years, especially Dr Peter 




A massive shout out to all my home friends for your inappropriate, insulting yet uplifting humour 
and friendships. Seven years on with a Brackley bond that is stronger than ever before, we are 
certainly the exception to the ‘you don’t stay in touch with your friends from school’ theory. My 
extended love goes to Leela Fair and Dani Skerrett for building a home from home with me here 
in London, from the wondrous birthday celebrations to deliverooing crêpes/churros/cheesecake 
on a mundane middle of the week evening and everything in between, the last few years would 
have been a lot less fun without you both. I would also like to thank Ichha Johar for her many 
words of wisdom and general life advice, and Helen Fielden for being an all-round great gal who 
constantly amuses me for all the right reasons. You are both wonderful and dependable friends 
that I am lucky to have. And lastly while on the topic of friends, I could write another 200 pages on 
my love and appreciation for my favourite person, Mai Ta. Thank you for your 21 (and counting) 
years of friendship, always being the voice on the end of the phone that can make anything seem 
a million times easier and without a doubt being the best friend anyone could even hope to have.   
 
To my Mum, Dad, brother and sister, thank you for being a constant bundle of unconditional love 
and support even when I’m mega annoying. I am endlessly grateful to my Mum for her nonchalant 
‘it’ll be fine but just get on with it’ attitude and my Dad for his charming comments like ‘you know 
40,000 words is only 40 words a day over four years’. You are wonderful parents who forever 
manage to strike the perfect balance between comfort, mockery and tough love to get me where 
I need to be. Sophie and Felix thanks for being stand up siblings, a joy to be around and generally 
just two of the best people I know. I am very pleased I accidentally completed our family all those 
years ago and am stuck with you all.  To my extended family- I promise you can now stop asking 
me what I do, what job I will get afterwards, if I’ve saved the world yet and whether I still give 
cancer to baby fish. Thanks for your ever-encouraging questions.  
 
And finally, last but definitely not least, I am incredibly grateful to my Grandad, who sadly passed 
away during my second year.  As a professional advocate of further education, he was always very 
encouraging of my studies. I wish I could show you this, but I will take comfort in the fact I would 




Breast cancer is a primary cause of cancer lethality in women due to its ability to 
metastasise to other organs. Currently there are no therapeutic interventions specifically 
targeting breast cancer metastasis. p-21 activated kinases (PAK 1-6) are recognised 
regulators of cell morphology and thus promotion of migration. Therefore, these proteins 
have been implicated in driving metastasis and many pharmaceutical companies have 
developed PAK programmes.  
 
In particular PAK1 is associated with breast cancer. The PAK1 gene is located in a genomic 
region which is frequently amplified in many breast cancers. Indeed, PAK1 is reported to 
be overexpressed and/or hyperactivated in over 50% of human breast cancers. However, 
the importance of PAK1 kinase activity over PAK1 protein interactions is not well 
established. This is crucial given many drug discovery programmes are focused on kinase 
inhibition. Furthermore, the downstream targets of PAK1 specifically in breast cancer are 
not fully described; especially those proteins most important for cell spreading. This 
project focuses on the role PAK1 plays in breast cancer cell spreading and migration, with 
an emphasis on unravelling the kinase dependent pathways.    
 
PAK1 depletion via shRNA and CRISPR-Cas9 technology in a triple negative breast cancer 
cell line caused a decrease in both cell spread area and cell migration. These findings were 
replicated using a pharmacological inhibitor of PAK1 kinase activity. The importance of 
PAK1 kinase activity in breast cancer cell migration was confirmed where pharmacological 
inhibition or depletion of PAK1 lead to a decrease in in vitro cell invasion and in vivo cell 
migration. Using an inducible system to stimulate PAK1 kinase activity a specific role in cell 
spreading was observed. Induction of cell spreading via PAK1 activation was associated 
with the serine 910 phosphorylation of FAK and serine 189 phosphorylation of ERK3. These 
are novel pathways in breast cancer. Taken together these results place PAK1 at the centre 
of cell spreading and migration and suggest that kinase activity is essential for these 
cellular responses. Thus, findings in this thesis support pharmaceutical inhibition of kinase 
activity as a valid therapeutic approach.   
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Chapter 1 Introduction 
1.1 Breast cancer  
Breast cancer is one of the most commonly diagnosed cancers with females having a 
12.3% lifetime probability of developing the disease (Rojas and Stuckey, 2016). Despite 
recent medical advances, it is the primary cause of cancer lethality in women (Jemal et al., 
2010). Five-year survival rates highlight the ongoing challenge of treating late stage 
diagnoses, with a survival rate of almost 100% of patients diagnosed with early stage 
breast cancers which is dramatically reduced to 21% for patients diagnosed with advanced 
disease (Hayat et al., 2007). Environmental factors such as obesity, alcohol consumption, 
cigarette smoking, oral contraceptives and increasing age can all influence the 
development of breast cancer (Rojas and Stuckey, 2016, Althuis et al., 2004). Genetic 
factors are also implicated in the development of the disease, with germline mutations in 
the BRCA1 and BRCA2 tumour suppressor genes being associated with a high lifetime risk 
of 60-85% for developing breast cancer (Ripperger et al., 2009).  
As breast cancer is a very heterogeneous disease, it is classified into distinct subtypes by 
specific molecular markers and clinical treatments (Banin Hirata et al., 2014). The human 
epidermal growth factor 2 (HER2) receptor is amplified in 30% of breast cancers and is 
associated with aggressive disease and therefore poor clinical outcomes (Banin Hirata et 
al., 2014). Although the development of trastuzumab, a monoclonal antibody which 
targets the HER2 receptor, has significantly improved outcomes (Banin Hirata et al., 2014). 
Hormone receptor positive tumours overexpress the oestrogen (ER) and progesterone 
(PR) receptors (Althuis et al., 2004). As these tumours are regulated by hormones, they 
respond to drugs which target the ER such a tamoxifen (Althuis et al., 2004). Tumours 
lacking the presence of both hormone and HER2 receptors are known as triple negative 





1.1.1 Triple negative breast cancer 
 Of all breast cancer cases diagnosed 10-20% are TNBC (Costa and Gradishar, 2017).  TNBC 
has a higher incidence in younger, obese and African American women (Lebert et al., 
2018).  
TNBC are highly heterogeneous and several attempts to classify TNBC into subtypes have 
been attempted however they are yet to deliver clinical utility (Bianchini et al., 2016). 
Chemotherapy is the mainstay treatment for TNBC as there is a distinct lack of targeted 
therapies available for this type of breast cancer (Hudis and Gianni, 2011) highlighting the 
need for the identification of new therapeutic targets. TNBC are associated with poor 
prognosis, short progression free and overall survival (Costa and Gradishar, 2017). In fact, 
on diagnosis TNBC have often already metastasised to the surrounding lymph nodes and 
are more likely to be diagnosed at a later stage than other forms of breast cancer, due to 
their more aggressive nature (Dent et al., 2007).  
 
1.1.2 Tumour metastasis  
Metastatic disease is the leading cause of cancer mortality (Jemal et al., 2010) and is 
responsible for approximately 90% of cancer deaths despite the improvements in cancer 
diagnosis, chemotherapies and surgical techniques (Valastyan and Weinberg, 2011).  This 
highlights the need to develop a clinical strategy to supress metastasis.  The metastatic 
cascade’s multistep nature offers various molecular opportunities for pharmacological 
intervention, however understanding the molecular mechanisms is crucial to identify 
novel therapeutic targets  (Palmer et al., 2011). 
Metastatic disease is the dissemination of cancer cells from the primary site of origin to 
distant non-native tissue. Cancer cells invade into the surrounding stroma and 
neighbouring tissues, leading to intravasation into the bloodstream. These cells are then 
transported via the circulation, extravasate out of the bloodstream and proliferate to form 
distant metastases (Valastyan and Weinberg, 2011) (Figure 1.1). This process, known as 
the metastatic cascade, involves the tight co-ordination of cell motility and invasion away 
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from the primary tumour, cell survival in non-permissive environments and proliferation 
at distant sites.  
Epithelial to mesenchymal transition (EMT) is associated with metastasis as non-invasive 
cancer cells from the primary tumour transform into migratory and motile cells. SNAIL, 
TWIST and TGFβ signalling are key inducers of EMT as they regulate early events of the 
transition such as loss of E-cadherin expression and apicobasal cell polarity (Thiery et al., 
2009). The mesenchymal phenotype characterised by front to rear polarity is established 
by the RhoGTPases when induced by extracellular signals such as hepatocyte growth 
factor (HGF), epidermal growth factor (EGF) and Insulin- like growth factor 1 (IGF1) 
(Lamouille et al., 2014). Once EMT has occurred, invasive cancer cells need to penetrate 
the basement membrane, this is achieved by secretion of matrix metalloproteases 
(MMPs), enzymes which degrade the extracellular matrix (ECM) (Kessenbrock et al., 2010). 
Increased expression of MMP9 is found to correlate with higher rates of metastasis in 
aggressive HER2 positive and triple negative breast cancers (Yousef et al., 2014). In animal 
models, inhibition of MMPs have been shown to prevent cancer cell invasion however 
they failed to improve clinical outcomes in human clinical trials (Kessenbrock et al., 2010). 
It is speculated that this is due to MMP function being more complex then degradation 
enzymes, as they also play a role in signalling pathways to regulate proliferation and 
apoptosis (Kessenbrock et al., 2010). Finally, once the invading cancer cells have 
penetrated the basement membrane, they interact with the tumour supporting stroma 
containing further environmental cues and a variety of cells including macrophages, 
adipocytes and endothelial cells, which further enhance invasive behaviour (Valastyan and 
Weinberg, 2011).  
Breast cancer is able to metastasise to other organs, most commonly the lungs, liver and 
bone (Weigelt et al., 2005). Different subtypes of breast cancer preferentially metastasise 
to different non-native sites. The bone is the most common site of hormone receptor 
positive breast cancers metastasis (Lorusso and Ruegg, 2012) whereas triple negative 
breast cancers rapidly spread to visceral organs such as the liver and lungs (Dent et al., 
2009). Only 6% of breast cancer patients initially present with metastatic disease at 
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diagnosis however 30% of patients diagnosed with early stage breast cancers will develop 
metastatic disease (O'Shaughnessy, 2005).  
Recently, a new term ‘migrastatics’ has been coined which specifically refers to drugs that 
interfere with all modes of cancer cell migration and invasion (Gandalovicova et al., 2017). 
Using antimetastatic drugs alongside antiproliferative therapy could prevent both the 


















































Figure 1.1 Schematic diagram of the metastatic cascade. Cells from the primary tumour penetrate 
the basement membrane and invade into the surround stromal tissue. Cells are then able to 
intravasate into the vasculature and lymphatic systems where they travel around the body. Cancer 




1.2 The importance of cell migration  
Cell migration is an essential process which plays a vital role in morphogenesis, wound 
healing, tissue repair and immune surveillance (Ridley et al., 2003). It’s a complex multi-
step and highly coordinated process that in the context of cancer can result in the 
formation of metastases (Valastyan and Weinberg, 2011). Understanding the mechanisms 
involved in cell migration and the metastatic cascade could provide novel therapeutic 
targets to prevent cancer metastasis.  
 
1.2.1 Modes of Cell migration  
In normal cells, migration can be grouped into mechanically distinct stages due to the 
regulation of the cytoskeleton, cell-cell adhesions and cell-matrix adhesions. Cells become 
polarised and produce broad protrusions and finger-like protrusions at the leading edge, 
termed lamellipodia and filopodia respectively. New cell-matrix adhesions are formed to 
anchor the cell to the ECM. This produces traction forces allowing cell body contraction 
(Friedl and Alexander, 2011). This coupled with the membrane retraction and degradation 
of cell adhesions at the rear of the cell results in forward movement and cell migration 
(Friedl and Alexander, 2011, Ridley, 2011). 
Cancer cells can migrate through the ECM during the metastatic cascade as either 
individual cells or as a group, termed single cell and collective migrations respectively 
(Friedl and Wolf, 2003, Sanz-Moreno and Marshall, 2010) (Figure 1.2). There are two 
methods of single cell migration, mesenchymal and amoeboid.  
Mesenchymal cells have a fibroblast-like elongated and polarised morphology and migrate 
in the multistep process similar that of normal cells. However mesenchymal migration 
relies on the secretion of MMPs form invadopodia, actin rich protrusions from the plasma 
membrane which degrade the ECM and permit invasion (Murphy and Courtneidge, 2011). 
Amoeboid migration occurs when cells of a spherical morphology, characterised by rapid 
deformability, squeeze through strands in the ECM. High intracellular hydrostatic pressure 
allows membrane blebs to form which sense the surrounding ECM. Amoeboid cells also 
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possess high actin myosin contractility and low adhesion forces meaning cell migration is 
driven by a propulsive mechanism (Friedl and Wolf, 2003).  
Collective cell migration occurs when multiple cells migrate as a group, this can be within 
sheets, clusters or streaming (Friedl and Wolf, 2010). During collective cell migration cell-
cell adhesions (such as cadherins) and cell-matrix adhesions (such as integrins) are not 
degraded (Sahai, 2005). Both types of cell migration, single and collective, are not mutually 
exclusive and can occur simultaneously in cancer migration (Friedl and Wolf, 2003). For 
example, in collective cell migration, migration tracks are formed by the presence of one 
or multiple leader cells with utilise a mesenchymal-like mode of migration to degrading 
the ECM ahead of the collective cell mass (Friedl, 2004). 
Cellular plasticity refers to the ability of a cell to modulate its phenotype based on its 
surrounding environment, this concept allows cancer cells to not only survive in but 
migrate through different tissues (Friedl and Alexander, 2011). Cellular morphology and 
mode of migration can differ greatly based on extracellular matrix properties and the 
adhesive and proteolytic capabilities of a cell (Friedl and Wolf, 2010). For example, cells in 
soft matrices favour an amoeboid-like mode of migration (Krakhmal et al., 2015) whereas 
a matrix of an increased stiffness in 3D migration promotes formation of focal adhesions 
and cell elongation which are both characteristics of mesenchymal-like migration (Friedl 
and Wolf, 2010). 
Furthermore, studies into breast cancer cells have demonstrated the ability of cells to 
adapt their mode of migration based on their proteolytic capacities. Untreated MDA-MB-
231 cells display a mesenchymal-like mode of migration, generating proteolytic 
degradation tracks in 3D collagen matrices, however when treated with protease 
inhibitors the cells migrate by propulsive squeezing between pre-existing gaps in the 





































Figure 1.2 A schematic diagram of the modes of cancer cell migration. Cells can invade by single 
cell or collective cell migration. Single cell migration consists of both mesenchymal and amoeboid 
modes of migration, characterised by elongated cells and matrix degradation, and rounding 
blebbing cells with high contractility respectively.  In collective cell migration, cells migrate with cell-




1.2.2 The role of cell spreading in cell migration  
Two distinct types of cell spreading occur and are reportedly studied in the literature; 
these are known as early and late spreading. Early spreading, also termed nascent 
spreading, refers to the initial attachment of a cell to a matrix or coverslip. Whilst both 
early cell spreading and cell migration require the deformation of the plasma membrane 
and formation of cell-matrix adhesions they are thought to be two distinct phenomena 
(McGrath, 2007). Fundamental differences between early and late spreading have been 
identified. Early cell spreading is a passive process while late cell spreading is an active 
process (McGrath, 2007).  
Early cell spreading can be grouped into three stages- the initial stage where the cell body 
attached to its substrate, the flattening and spreading of the cell body, and finally the 
formation of focal adhesions between the cell and its substrate and the organisation of 
the actin cytoskeleton (Khalili and Ahmad, 2015). When integrins, transmembrane 
proteins, are active they can bind components of the ECM to initiate the formation of cell-
matrix adhesions (Khalili and Ahmad, 2015). These initial integrin-mediated adhesions 
attach the cell actin cytoskeleton to the ECM and stimulate bidirectional signalling 
pathways (Khalili and Ahmad, 2015). A major group of proteins activated downstream of 
integrin and ECM binding are the Rho GTPases (Hall, 1998). Activation of Rho GTPases 
results in the organisation of the actin cytoskeleton, stabilisation of cell-ECM adhesions 
and cell spreading (Khalili and Ahmad, 2015).  
Late cell spreading involves actin polymerisation and myosin contraction causing polarised 
cells to crawl, a process that is essential at the leading edge of a migratory cell (McGrath, 
2007, Dobereiner et al., 2004, Dubin-Thaler et al., 2004). The Rho GTPases are known to 
play a critical role in late cell spreading during cell migration (Sit and Manser, 2011). Cell 
migration and therefore cancer metastasis is powered by the constant turnover and 




1.2.3 Actin dynamics in cell migration  
Cell migration is dependent on the dynamic processes of the actin cytoskeleton (Ridley et 
al., 2003).  The actin cytoskeleton is comprised of filamentous actin (F-actin) which are 
thin flexible polymeric fibres made up of individual monomers of globular actin (G-actin) 
(Jiang et al., 2009). In an adenosine triphosphate (ATP) dependent manner, G-actin is 
added to the fast-growing barbed end (+) of F-actin. Simultaneously, at the slow-growing 
pointed end of F-actin, hydrolysis of ATP on the G-actin monomers to adenosine 
diphosphate (ADP) causes these monomers to dissociate creating a functional polarity for 
F-actin (Jiang et al., 2009). The continuous assembly, disassembly and reorganisation of 
actin filaments is modulated by regulatory proteins, such as the actin-related proteins 2/3 
(Arp2/3) complex and capping proteins. The Arp2/3 complex is a seven-subunit protein 
complex which allows branching of F-actin by creating new nucleation cores ensuring 
continuous assembly of F-actin at the leading edge of a migratory cell (Welch et al., 1997). 
Capping proteins, such as CapZ and gelsolin, ensure a defined cell shape for migration as 
they bind the barbed ends of F-actin to prevent the association and dissociation of G-actin 
(Cooper and Sept, 2008).  
Different geometric organisation of F-actin allows the formation of various architectural 
structures which influence cell migration. For example, branched and cross-linked 
filaments constitute lamellipodia formation whereas parallel actin filaments constitute 
filopodia formation (Blanchoin et al., 2014). Finally, a network of cross-linked actin 
filaments causes the formation of stress fibres, an entity which provides the structural 
basis for maturation of focal adhesions, another important regulator of cell migration 
(Blanchoin et al., 2014). 
 
1.2.4 Focal adhesions in cell migration  
Focal adhesions allow attachment of the cell to the ECM and are essential for many 
processes such as cellular proliferation, survival, differentiation, cellular morphology and 
migration (Nagano et al., 2012). Tight control of their assembly and disassembly is crucial 
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for efficient cell migration. Firstly, the protrusions forming at the leading edge of a 
migrating cell need to be stabilised. Nascent adhesions form under the lamellipodia which 
activate proteins to cause actin polymerisation resulting in subsequent protrusions. 
Failure of adhesion formation at the leading edge results in membrane ruffle formation 
without distinct polarity (Parsons et al., 2010). The nascent adhesions mature and 
generate tension forces to enable cell contractility. In contrast, adhesions at thea rear of 
the cell must dissociate for cell retraction to occur, allowing movement in the direction of 
migration (Nagano et al., 2012).  
 
Focal adhesions form when transmembrane integrins cluster at the site of cell-ECM 
contact. The intracellular domains of the integrins recruit scaffold/adaptor which connect 
the focal adhesions to the cell’s actin cytoskeleton. Important adaptor proteins are talin, 
paxillin, vinculin, zyxin, tensin and α-actinin (Huttenlocher and Horwitz, 2011) . The linkage 
of focal adhesions and actin cytoskeleton generates tension and traction forces necessary 
for cell morphology and migration respectively (Nagano et al., 2012). 
Integrins also recruit signalling proteins which transmit extracellular signals to their 
downstream effectors resulting in cellular responses such as proliferation, survival and 
migration (Huttenlocher and Horwitz, 2011). Integrins have no enzymatic activity and 
therefore rely on signalling proteins to transmit signals to cellular machinery via signalling 
cascades. One of the most noted and important signalling proteins in focal adhesions is 
focal adhesion kinase (FAK) (Huttenlocher and Horwitz, 2011).  
 
1.2.5 Focal adhesion kinase 
FAK is a cytoplasmic tyrosine kinase heavily implicated in the turnover of focal adhesions 
and therefore cell migration (Nagano et al., 2012). Cells from FAK knockout mice have an 
increase number of focal adhesions and reduced mobility (Ilic et al., 1995). Furthermore, 
both cancer cells and fibroblasts with FAK depletion have higher numbers of larger 
peripheral adhesions with impaired turnover and reduced migration (Sieg et al., 2000, Hsia 
et al., 2003, Webb et al., 2004, Chan et al., 2009). 
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Multiple pathways implicate FAK in focal adhesion turnover. A downstream target of FAK, 
paxillin, is a key regulator of adhesion dynamics (Brown et al., 2005) as it is associated with 
many effector proteins, including GIT1, PAK1-interacting exchange factor (PIX) and p21-
activated kinase (PAK), all of which have a known involvement of focal adhesion regulation 
(Ballestrem et al., 2006). Further, FAK is able to cause adhesion disassembly through 
interactions with cytoskeletal regulatory proteins or regulation of calpain, extracellular-
signals regulated kinase (ERK) and myosin-light chain kinase (MLCK) (Webb et al., 2004, 
Carragher et al., 2003).  
Although there are many ways in which FAK can influence focal adhesion turnover the 
most established and studied mechanism is by the ability of FAK to regulate the Rho 
GTPases. The scaffold function FAK possesses plays an important role in recruiting proteins 
which can activate or inhibit the Rho GTPases, which are the master regulators of cell 
























1.3 The Rho GTPase family  
The Rho GTPases form a subgroup of the Ras-like protein superfamily of GTPases. Twenty 
human Rho GTPases have been identified and are involved in a wide range of cellular 
processes such as cell division, transcriptional regulation, phagocytosis, vesicular 
trafficking, cytoskeletal regulation, cell migration and cell adhesions (Jaffe and Hall, 2005). 
The Rho GTPases are divided into two groups - classical and atypical Rho GTPases. Classical 
Rho GTPases are the best studied in actin cytoskeletal regulation and cell motility (Sit and 
Manser, 2011). 
The classical Rho GTPases act as molecular switches that cycle between an inactive GDP-
bound conformation and an active GTP-bound conformation. In this active conformation 
the Rho GTPases can interact with their downstream target proteins to induce cellular 
responses (Figure 1.3). There are three types of protein that can regulate classical Rho 
GTPases. GTPase-activating proteins (GAPs) enhance the intrinsic GTP hydrolysis activity 
of the Rho GTPases rendering them inactive whereas guanine nucleotide exchange factors 
(GEFs) activate the Rho GTPases by promoting the exchange of GDP to GTP (Bos et al., 
2007). Finally, Rho guanine-nucleotide-dissociation inhibitors (GDIs) bind the GDP-bound 
Rho GTPase proteins sequestering the inactive protein in the cytosol extracting them from 
cellular membranes and preventing downstream signalling (Fukumoto et al., 1990, 
Leonard et al., 1992).  The most studied role of the RhoGTPases is their ability to regulate 
cell migration. This concept stems from observations that the Rho GTPase proteins can 






























Figure 1.3 Regulation of the Rho GTPases. GDIs sequester Rho GTPases in the cytoplasm, away from 
sites of activation and prevents their downstream signalling. At the plasma membrane inactive GDP-
bound Rho GTPases are activated by GEFs allowing signalling to downstream proteins causing 




1.3.1 Rho GTPases in cell migration 
The three most characterised Rho GTPases in cell motility and organisation of the actin 
cytoskeleton are Ras homolog gene family member A (RhoA), Ras-related C3 botulinum 
toxin substrate 1 (Rac1) and cell division control protein 42 (Cdc42) and will therefore be 
discussed herein (Sit and Manser, 2011). Both Rac1 and Cdc42 drive cell migration as they 
aid the formation of actin based protrusive structures at the cells leading edge. Rac1 
activity is required for the formation of lamellipodia whereas Cdc42 activity is associated 
with the formation of filopodia (Nobes and Hall, 1995). Interestingly Cdc42 and Rac are 
also implicated in the formation of filopodia and lamellipodia in nascent cell spreading 
(Price et al., 1998). Initial studies of RhoA highlight its importance in cell body contraction 
however the recent development of RhoA biosensors have indicated a role for RhoA in the 
formation of membrane ruffles at the cells’ leading edge (Donnelly et al., 2014).  
Rac1, Cdc42 and RhoA’s downstream targets and their roles in cytoskeletal regulation 
have been well studied. Rac1 and Cdc42 can initiate the formation of SCAR/WAVE 
(suppressor of cAMP receptor/WASP verprolin-homologous) and WASP (Wiskott-Aldrich 
Syndrome Protein) respectively (Parsons et al., 2010) (Figure 1.4). The formation of 
SCAR/WAVE and WASP activates the Arp2/3 complex allowing actin nucleation and 
branching to occur (Parsons et al., 2010). Rac1 also plays a role in the removal of capping 
proteins from the barbed ends of F-actin, allowing actin polymerisation. 
Phosphatidylinositol-4,5-bisphosphate (PIP2) can remove capping proteins such as 
gelsolin when synthesised on Rac1 binding to phosphatidylinositol-4-phosphate 5-kinase 
(PIP 5-kinase) (Tolias et al., 2000) (Figure 1.4).  
Rac1, Cdc42 and RhoA are all able to regulate cofilin via LIM kinase (LIMK). Rac1 and Cdc42 
activate PAK1 which in turn phosphorylates and activates LIMK (Edwards et al., 1999) 
(Figure 1.4). RhoA activates ROCK (Rho-associated, coiled-coil containing protein kinase 1) 
which is also able to activate LIMK (Ohashi et al., 2000) (Figure 1.4). Once activated, LIMK 
can phosphorylate cofilin to inactivate and inhibit its actin severing activity allowing actin 
filament stabilisation and growth (contractility, as ROCK can directly phosphorylate 
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myosin-light chain (MLC) and also inhibit MLC phosphatase (Fukata et al., 2001, Parri and 
Chiarugi, 2010) (Figure 1.4). A formin, Diaphanous-related formin (mDia), also activated 
downstream of RhoA, enables the addition of G-actin monomers to the barbed end of F-
actin allowing actin polymerisation (Jaffe and Hall, 2005) (Figure 1.4).  
 
 
Rac1, Cdc42 and RhoA are implicated in the formation of focal adhesions which play an 
essential role in cell migration. ROCK and mDia activation downstream of RhoA promotes 
the formation of dorsal stress fibres (Le Clainche and Carlier, 2008) (Figure 1.4). Focal 
adhesions associate to the end of stress fibres at the plasma membrane during cell motility 
(Ridley and Hall, 1992). This connection enhances cell contractility (Huttenlocher and 
Horwitz, 2011). RhoA also plays a role in the maturation of focal contacts, whilst Rac1 and 
Cdc42 are responsible for the formation of initial focal attachments to the ECM (Nobes 
and Hall, 1995, Ridley and Hall, 1992, Rottner et al., 1999).  
 
The Rho GTPases also regulate focal adhesion turnover, another vital process required for 
efficient cell migration. Upon Rac1 induced activation, PAK1 can interact with paxillin to 
cause the disassembly of focal adhesions (Zhao et al., 2000, Ridley, 2001). Further to its 
role in cell contractility, RhoA is responsible for focal adhesion disassembly at the rear of 
the cell causing cell retraction in the direction of migration (Huttenlocher and Horwitz, 
2011).  
 
As the Rho GTPases have differing roles in cell migration there is tight spatial and temporal 
regulation of the proteins which in part is maintained by significant cross talk between 
these three Rho GTPases. RhoA and Rac1 have an antagonistic relationship. RhoA can 
inhibit Rac1 activity by activating the Rac-GAP, ARHGAP22 (Parri and Chiarugi, 2010) 
(Figure 1.4). However, Rac1 can inhibit RhoA activity by activation of a Rho GAP called 
p190RhoGAP (Mammoto et al., 2007) (Figure 1.4). This results in a bistable relationship 
between the two Rho GTPases ensuring efficient cell migration as high Rac1 and low RhoA 
activity is required for cells to protrude whereas low Rac1 and high RhoA activity is 
required for cell contraction (Byrne et al., 2016). Interestingly FAK plays a role in interplay 
between RhoA and Rac1 in adhesion turnover. FAK deficient fibroblasts exhibit 
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constitutively active RhoA activity which stabilises adhesions (Ilic et al., 1995). However, 
FAK signalling can also activate p190RhoGAP to inhibit Rho activity and recruit and activate 
a Rac containing complex (Schober et al., 2007).  
 
Cdc42 can also regulate the activity of both RhoA and Rac1. The Cdc42-ßPIX complex 
formed at the cells leading edge during cell motility binds to srGAP1, a protein which 
suppresses RhoA activity (Kutys and Yamada, 2014) (Figure 1.4). Interestingly ßPIX is a Rac-
GEF which is activated by Cdc42. Cdc42’s ability to activate the Rac-GEFs such as ßPIX and  
TIAM1, in turn activates Rac1 and recruits it to the front of the cell to maintain cell polarity 
and directional migration (Cau and Hall, 2005) (Figure 1.4). 
 
The Rho GTPases have many downstream effectors influencing cell migration. The most 
notably downstream effectors of Rac1 and Cdc42 are the PAK family which also play an 
important role in the regulation of the cytoskeleton and focal adhesions during cell 



















Figure 1.4 Rho GTPase effector pathways that regulate cytoskeletal dynamics. Cdc42 and 
Rac1 are predominantly associated with filopodia and lamellipodia formation respectively. 
This occurs by the activation of LIMK via PAK1 to inhibit cofilin’s actin severing abilities and 
by promoting the formation of the Arp2/3 complex via WASP for Cdc42 and SCAR/WAVE for 
Rac1. Rac1 is also implicated in the PIP5-PIP2 signalling pathway which results in uncapping 
of actin filaments. RhoA signals to mDia and ROCK causing formation of stress fibres and 
actin polymerisation, as ROCK can inhibit cofilin via LIMK. RhoA signalling via ROCK also 
causes an increase in MLC phosphorylation inducing actin contractility. Cross talk between 
the RhoGTPases ensures efficient cell migration. Cdc42 can enhance Rac1 activation via 
TIAM1 and βPIX and inhibit RhoA activity via βPIX and srGAP1. RhoA activates ARHGAP22 to 




1.4 The p-21 activated kinase family  
The PAK family is a family of serine/threonine kinases involved in a wide range of cellular 
processes such as cell survival, proliferation, motility and gene transcription (King et al., 
2014). There are six members of the family, divided into two groups, PAK1-3 (group I) and 
PAK4-6 (group II) based on similarities in their sequences, domains and regulation (Arias-
Romero and Chernoff, 2008) (Figure1.5). The PAK proteins are highly conserved in a wide 
range of organisms including yeast, Caenorhabditis elegans, Drosophila melanogaster and 
humans (Bokoch, 2003).  
All group I PAKs exhibit high expression in the brain, especially PAK3 where this protein is 
predominantly expressed (Arias-Romero and Chernoff, 2008). Indeed, the PAK3 knockout 
mouse model exhibits abnormalities in synaptic plasticity and defects in learning and 
memory (Kelly and Chernoff, 2012). PAK2 is ubiquitously expressed and the PAK2 
knockout mouse model is lethal at E8 due to developmental defects (Kelly and Chernoff, 
2012). PAK1 is found at high levels in the heart, liver, spleen and muscle. The PAK1 mouse 
knockout model is viable but exhibits immune, glucose homeostasis and neuronal defects, 
and cardiac hypertrophy on pressure overload (Kelly and Chernoff, 2012). PAK4 is 
expressed highly throughout development and knock out of the protein is embryonically 
lethal at E11.5 in mice, owing to foetal heart defects, such as enlargement of the right 
atria and ventricle and thinning of the myocardium (Qu et al., 2003). In adulthood is it 
thought to be ubiquitously expressed with high levels present in the colon, prostate and 
testis (Kelly and Chernoff, 2012). PAK6 is also found at high levels in the prostate and testis, 
as well as the placenta, breast, brain and kidney (Kelly and Chernoff, 2012). Finally, PAK5 
is expressed in the pancreas, testes, prostate and adrenal gland. Both the PAK5 and PAK6 





Figure 1.5 p21-activated kinase family structures. The structures of group I (PAK1-3) and group II 
(PAK4-6) PAKs. All PAKs have an N-terminal p21-GTPase binding domain (GBD) and a C-terminal 
kinase domain. Group I PAKs also contain an autoinhibitory domain (AID), a PIX binding site 
(purple), a putative integrin binding site (dark red) and variable numbers of proline rich regions 
(blue). The group II PAKs all also contain variable numbers of the proline rich regions and a putative 
AID. PAK3 and 4 contain, like the group I PAKs, a putative integrin binding site (dark red). PAK4 
contains a GEF/GRB2-associated-binding protein 1 (Gab1) interacting domain (GID) (pink) and the 




1.4.1 PAK domain structure and regulation 
All six PAK proteins possess an N-terminal p21-GTPase-binding domain (GBD) and a highly 
conserved C-terminal serine/threonine kinase domain (Arias-Romero and Chernoff, 2008) 
(Figure 1.5). However intervening sequences differ between group I and group II PAKs 
leading to differences in regulation.  
Group I PAKs have an autoinhibitory domain (AID) which overlaps the N-terminal GBD, 
blocking protein activation (Lei et al., 2000). Inactive group I PAKS form inhibitory trans-
homodimers where an AID of one protein will inhibit the kinase domain of another (Parrini 
et al., 2002). The main method of activation for group I PAKs is the binding of the 
RhoGTPases, Cdc42 and Rac1, to the GBD (Table 1.1). This releases the dimer and allows 
the PAK to autophosphorylate itself at threonine 423, threonine 402 and threonine 421 
for PAK1, PAK2 and PAK3 respectively, rendering the proteins active (Zenke et al., 1999, 
Arias-Romero and Chernoff, 2008) (Figure 1.6). The ability of PAK2 and PAK3 to form 
homodimers has not previously been investigated however due to their high sequence 
homology within the binding sites to PAK1 it is assumed they are capable of dimerization 
(Combeau et al., 2012). Interestingly the PAK3 gene can produce spliced variant of the 
protein that are constitutively active. These variants favour heterodimerisation with PAK1 
rather than homodimers (Kreis et al., 2008, Combeau et al., 2012). 
Many proteins including the Rho GTPases can influence PAK1 activity by protein-protein 
interactions. Group I PAKs have N terminal non-catalytic region of tyrosine kinase adaptor 
protein (Nck) binding sites (Figure 1.5) (Table 1.1). On Nck binding to PAK1 it is localised 
to the plasma membrane where Rho GTPases can activate it (Lu and Mayer, 1999). Other 
adaptor proteins such as growth factor receptor-bound protein 2 (Grb2) can influence 
PAK1 activity (Table 1.1). On PAK1 and Grb2 binding, via the N terminal proline region of 
PAK1 and an SH3 domain on Grb2, the PAK1/Grb2 complex localises to the plasma 
membrane. Here PAK1 can be activated by the epidermal growth factor receptor (EGFR) 
(Puto et al., 2003). Active 3-phosphoinositide-dependent kinase 1 (PDK1) in the presence 
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of sphingosine can also activate PAK1 by phosphorylating it at threonine 423, its 
autophosphorylation site (King et al., 2000) (Table 1.1). 
PAK1 can also be negatively regulated by protein-protein interactions. Many proteins such 
as PKA (protein kinase A), PP2A (phosphatase type 2A) and POPX1 and POPX2 (partner of 
PIX 1 and 2) can dephosphorylate PAK1 rendering it inactive (Howe and Juliano, 2000, Koh 
et al., 2002) (Table 1.1). Proteins which directly bind the N-terminus of PAK1 can cause an 
inhibitory effect on PAK1 activity such as human PAK1-interacting protein, CRIPak 
(cysteine rich inhibitor of PAK1) and merlin (Talukder et al., 2006, Xia et al., 2001, Kissil et 
al., 2003) (Table 1.1).  Finally, a microRNA (miR-7) targets the 3’-untranslated region of 
PAK1 mRNA inhibiting its translation into the PAK1 protein (Reddy et al., 2008). 
 
The method of regulation of group II PAKs remains controversial. It was previously thought 
PAK4 activity was dependent on phosphorylation at serine 474 however this site has been 
demonstrated to be constitutively phosphorylated (Ha et al., 2012). Two proposed 
mechanisms of PAK4 activation exist. The first mechanism asserts it is in a very similar 
manner to how group I PAKs are regulated. It is thought there is an N-terminal region, an 
AID at amino acids 20-68, binds the GBD and holds PAK4 in an inactive form. Upon Cdc42 
binding to the GBD, there is a conformational change which allows PAK4 to become active 
(Baskaran et al., 2012) (Figure 1.6). The second mechanism asserts an N-terminal 
pseudosubstrate motif with a crucial proline residue (R49PKPLV) inhibits the kinase domain 
and subsequently the kinase activity of PAK4. Activation occurs when a protein containing 
an SH3 domain binds PAK4, allowing the autoinhibition to be relieved (Ha et al., 2012) 
(Figure 1.6). 
Being the most notable downstream effectors of Cdc42 and Rac1 the PAKs, like the 
RhoGTPases, play a key role in proliferation, the cell cycle, cell movement and apoptosis. 
As these cellular processes are heavily involved in cancer survival and progression, it is not 
surprising the PAKs are implicated in many cancer types. The PAK1 isoform is the most 




Figure 1.6 Regulation of group I and group II PAKs. Inactive group I PAKs form homodimers where 
the AID of one monomer inhibits the kinase activity on the opposing monomer, and visa versa. The 
homodimers dissociate on Rho GTPase binding to the GBD domain. This allows 
autophosphorylation to occur and therefore the activation of the group I PAKs. Phosphorylation 
of the kinase domain is indicated by a P (pink) and an active kinase domain is indicated by the 
presence of a star (purple). There are two proposed mechanisms for group II PAK activation. First, 
the AID of the PAK inhibits the kinase domain on the same protein. On Rho GTPase binding to the 
GBD the AID domain releases the kinase domain rendering it active. The second group II activation 
mechanism places an N terminal psuedodomain (orange) in the kinase cleft causing kinase 
inactivity. On binding on an SH3 domain containing protein the psudeosubstrate releases the 









Cdc42 Regulator Activates PAK1 by binding to the GBD 
and relieving PAK1 heterodimerisaton  
King et al. 
(2014) 
Rac1 Regulator  Activates PAK1 by binding to the GBD 
and relieving PAK1 heterodimerisaton  
King et al. 
(2014) 





Grb2 Regulator  Binds and translocates PAK1 to the 
plasma membrane 
Puto et al. 
(2003) 
PDK1 Regulator Phosphorylate and activate PAK1 King et al. 
(2000) 





PP2A Regulator Dephosphorylation and inactivation of 
PAK1 




Regulator Dephosphorylation and inactivation of 
PAK1 
Koh et al. 
(2000) 




Merlin Regulator  Binds N terminal of PAK1 inhibiting its 
activation 
Kissil et al. 
(2003) 
ER Effector PAK1 phosphorylates to promote ER 
signalling  
Holm et al. 
(2006) 
LIMK Effector  PAK1 phosphorylates to activate thus 
causing downstream inhibition of 
cofilin allowing actin polymerisation  
Edwards et 
al. (1999) 







Effector  PAK1 phosphorylates to induce cellular 





Effector PAK1 binds to induce membrane 
ruffling 
Vadlamudi 
et al. (2002) 
P41-Arc Effector PAK1 phosphorylates to promote 
formations of the Arp2/3 complex 
Vadlamudi 
et al. (2004) 
PDK1 Effector   
Raf Effector PAK1 phosphorylates to promote 
MAPK signalling  
Aksamitiene 
et al. (2011) 
Mek Effector PAK1 phosphorylates to promote 
MAPK signalling  
Aksamitiene 
et al. (2011) 
Paxillin Effector PAK1 phosphorylates to promote GIT1 
binding causing translocation to focal 
adhesions  
Nayal et al. 
(2006) 
Snail Effector PAK1 phosphorylates causing 
translocation to the nucleus inhibiting 
e-cadherin expression  
Whale et al. 
(2011) 
Elloul et al. 
(2010) 
CRKII Effector PAK1 phosphorylates to cause a 
downstream decrease in p120-catenin 
expression  
Rettig et al. 
(2012) 








1.4.2 PAK1 in cancer 
PAK1 is thought to be involved in multiple aspects of cancer, including cell proliferation 
and survival, as well as resistance to apoptosis and cell migration due to three different 
alterations (King et al., 2014) (Table 1.2). PAK1 overexpression has been linked to breast, 
colorectal, endometrial, gastric, lung, melanoma, ovarian, pancreatic, prostate and 
squamous cell carcinomas (King et al., 2014) (Table 1.2). PAK1 sits at 11q13 in the genome, 
an area which is often amplified in breast cancer (Bekri et al., 1997). Genomic amplification 
of PAK1 is also present in bladder, melanoma, ovarian, and T cell lymphomas (King et al., 
2014) (Table 1.2). Finally, increased phosphorylation of PAK1 is associated with breast, 
glioblastoma, kidney and ovarian cancers (King et al., 2014) (Table 1.2).  
These aberrations of PAK1 expression results in higher PAK1 activity in many cancer cell 
types. PAK1 is implicated in many of these tumour types due to its ability to aid the 
development and progression of cancers (King et al., 2014).  
Interestingly the localisation of PAK1 influences cancer progression. An increased level of 
phosphorylated PAK1 in the cytoplasm is correlated with a reduced survival time in 
patients with glioblastoma patients (Aoki et al., 2007).  When under the control of a ß-
lactoglobulin promoter in mice, a constitutive active PAK1 mutant induced mammary 
gland tumours, demonstrating PAK1’s role in breast cancer formation (Wang et al., 2006). 
In this mouse mammary tumour model nuclear localisation of PAK1 is correlated with the 
progression of ductal hyperplasia to adenocarcinoma (Wang et al., 2006). Nuclear 
localisation of PAK1, in the form of phosphorylated PAK1, is able to phosphorylate the ER 
at serine 305, which has also been linked to tamoxifen resistance in ER positive breast 
cancer patients (Holm et al., 2006, Rayala and Kumar, 2007).  
PAK1 has a particular importance in breast cancer as it is reported to be implicated in over 
50% of breast cancers (Ong et al., 2011).  Whilst linked to other aspects of cancer growth 







Cancer Type Alteration in cancer References 
Bladder Genomic amplification Ito et al. (2007) 





Balasenthil et al. (2004) 
 
Ong et al. (2011) 
 
Bostner et al. (2007) 
Stofega et al. (2004) 
Vadlamudi et al. (2000) 
Colorectal Protein overexpression Carter et al. (2004) 
Endometrial Protein overexpression Lu et al. (2013) 
Gastric Protein overexpression Wu et al. (2014) 
Glioblastoma Increased phosphorylation Aoki et al. (2007) 
Kidney Increased phosphorylation O'Sullivan et al. (2007) 
Lung Protein overexpression Ong et al. (2011) 
Melanoma Genomic amplification 
 
Protein overexpression 
Ong et al. (2013) 
 
Ong et al. (2013) 







Brown et al. (2008) 
Schraml et al. (2003) 
 
Davidson et al. (2008) 
Siu et al. (2010) 
 
Siu et al. (2010) 
Pancreatic Protein overexpression Zhou et al. (2014) 
Prostate Protein overexpression Goc et al. (2013) 
Squamous cell 
carcinoma 
Protein overexpression Chow et al. (2012) 
T -cell lymphoma Genomic amplification Mao et al. (2003) 
Table 1.2 PAK1 alterations in human cancers. 
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1.4.3 PAK1 in cell motility and cancer cell migration 
PAK1 was first identified in 1994 due to its activation by the Rho GTPases (Manser et al., 
1994). In non-cancerous cells PAK1 has been found to localise to the leading cell edge of 
migrating cells (Dharmawardhane et al., 1999, Nayal et al., 2006, Parrini et al., 2009, Sells 
et al., 2000), cell-cell junctions (Zegers et al., 2003) and focal adhesions (Delorme-Walker 
et al., 2011). It is therefore not surprisingly that PAK1 is able to influence cell migration 
due to its capabilities to regulate the actin cytoskeleton, focal adhesions and cell-cell 
junctions Studies of PAK1 in cancer cell lines also highlight the importance of its function 
in cell migration and invasion. It has previously been demonstrated to play a role in 
melanoma (Pavey et al., 2006), prostate (Goc et al., 2013), breast (Adam et al., 2000) and 
ovarian cancer (Siu et al., 2010) cell migration.  
 
Studies in both non-cancerous and cancerous cell types have elucidated the mechanisms 
by which PAK1 can influence cell migration. PAK1 can regulate the actin cytoskeleton via 
several different signalling pathways and localises to cortical actin structures on PDGF 
stimulations (Dharmawardhane et al., 1997).  As previously mentioned, it can 
phosphorylate LIMK when activated by Cdc42 and Rac1 resulting in inhibition of cofilin’s 
actin severing function allowing the formation of membrane protrusions due to actin 
polymerisation (Edwards et al., 1999, Arber et al., 1998, Yang et al., 1998) (Table 1.1). 
PAK1 can also phosphorylate myosin light chains directly, inducing cellular contractility 
and stress fibre formation (Stockton et al., 2004) (Table 1.1). PAK1 is also able to influence 
the cytoskeleton by interactions with actin binding proteins. PAK1 is able to induce 
membrane ruffling by interacting with filamin A (Vadlamudi et al., 2002) and is able to 
promote the formation of the Arp2/3 complex by phosphorylating the p41-Arc a subunit 
(Vadlamudi et al., 2004) (Table 1.1). This results in enhanced actin polymerisation in breast 
cancer cell migration (Vadlamudi et al., 2004).  
 
PAK1 has also been implicated in Akt signalling and cell migration (Huynh et al., 2010). 
When activated by Rac1, PAK1 acts as a scaffold to induce Akt stimulation via PDK1. PAK1 
is also able to recruit Akt to the membrane in motile cells (Higuchi et al., 2008) and can 
enhance migration and invasion of colon cancer cells (Huynh et al., 2010).  
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In addition to Akt signalling, PAK1 is also involved in MAPK signalling. PAK1 is able to 
phosphorylate Raf1 and MEK1 on sites serine 338 and serine 298 respectively  (King et al., 
2014). Phosphorylation of these sites increases the association of Raf with MEK and MEK 
with ERK thus further stimulating MAPK signalling (Aksamitiene et al., 2012) (Table 1.1).    
Expression of constitutively active PAK1 results in MAPK signalling and anchorage 
independent growth in breast cancer cells (Vadlamudi et al., 2000). Further to this, 
activation of HER2 in ER positive breast tumours results in PAK1 activation, via Rac1, 
causing epithelial breast cells to proliferate and transform via the MAPK pathway (Arias-
Romero et al., 2010). PAK1 signalling via the MAPK cascade can induce the formation of 
lamellipodia (Smith et al., 2008). Finally, PAK1 signalling has also been shown to enhance 
the formation of invadopodia, protrusions formed by cancer cells (Ayala et al., 2008, 
Nicholas et al., 2016) and induce them to secrete MMPs (Rider et al., 2013).  
 
PAK1 is also able to regulate the disassembly of focal adhesions, an important part of cell 
migration. Expression of constitutively active PAK1 causes a reduction in the number of 
focal adhesions (Manser et al., 1997) and focal adhesions turnover is disrupted upon the 
inhibition of PAK1 (Delorme-Walker et al., 2011). Group I PAKs have a PIX binding domain 
(Manser et al., 1998) (Figure 1.5). This binding localises PAK1 to focal adhesions where it 
can bind paxillin, one of the major components of focal adhesions (Brown et al., 2002). 
The binding of PAK1 with paxillin is thought to play a role in the dissolution of focal 
adhesions (Ridley, 2001, Zhao et al., 2000). Phosphorylation of paxillin at serine 273 by 
PAK1 causes GIT1 binding to paxillin. The GIT1-PIX-PAK1 complex is recruited to the cells 
leading edge promoting focal adhesion turnover and Rac induced protrusions (Nayal et al., 
2006) (Table 1.1). However, PAK1 phosphorylation of paxillin at serine 273 has been 
disputed (Dart et al., 2015).   
 
As well as focal adhesions, PAK1 has also been shown to regulate cell-cell adhesions and 
therefore influence cancer cell migration. Interestingly depletion of PAK1 in prostate 
cancer cells inhibits the disassembly of cell-cell junctions  (Bright et al., 2009). PAK1 can 
phosphorylate and translocate the zinc finger protein Snail to the nucleus. Snail is then 
able to prevent E-cadherin expression causing a decrease in E-cadherin cell to cell 
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junctions, which promotes cell to cell dissociation  (Whale et al., 2011, Elloul et al., 2010) 
(Table 1.1). In ovarian cancer cell lines this has been shown to promote EMT (Elloul et al., 
2010). PAK1 also influences E-cadherin as it is required for E-cadherin disassembly at cell 
junctions downstream of Rac1 (Lozano et al., 2008).  PAK1 can also cause a reduction in E-
cadherin and other cell to cell junction proteins, such as p120-catenin by phosphorylation 
of CRKII which is able to downregulate these junctional proteins (Table 1.1). Silencing 
PAK1 in nonsmall cell lung cancer cells increases the p120-catenin levels and decreases 
the motility and invasiveness of these cells (Rettig et al., 2012). It is therefore thought 
PAK1 can promote cell motility and invasiveness of nonsmall cell lung cancer cells by down 













1.5 Project aims 
The aim of this project was to investigate the importance of PAK1 kinase activity during 
breast cancer cell spreading and migration and identify potential downstream signalling 
pathways involved in these processes. Specific objectives comprise the following: 
 Assess the effect of perturbation, via depletion and pharmacological inhibition, of 
PAK1 on cell morphology and 2D migration  
 
 Access the requirement for PAK1 kinase activity in in vitro cell invasion and in vivo 
cell migration   
 
 Utilise an inducible PAK1 model system to monitor PAK1 specific cellular responses 



















Chapter 2  
Materials and methods  
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Chapter 2 Materials and methods 
2.1 Materials 
2.1.1 General materials  
Reagent Company 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) A&E scientific 
4',6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich, UK 
Acetic acid Sigma-Aldrich, UK 
Acrylamide (30%) Severn Biotech Ltd, UK 
Agarose Invitrogen, UK 
Alexa Fluor® 488 Phalloidin Invitrogen, UK 
Ammonium persulfate (APS) Sigma-Aldrich, UK 
Aprotinin Sigma-Aldrich, UK 
Beta (β)- mercaptoethanol Sigma-Aldrich, UK 
Borosilicate glass capillary, 1.0mm outer diameter x 0.58mm 
inner diameter 
Harvard Apparatus, USA 
Borosilicate glass capillary, 1.0mm outer diameter x 0.78mm 
inner diameter 
Harvard Apparatus, USA 
Bovine serum albumin (BSA) VWR International, UK 
Bromophenol blue Bio-Rad 
Calcium chloride (CaCl2) Sigma-Aldrich, UK 
Calcium phosphate transfection kit Invitrogen, UK 
Cell dissociation buffer Sigma-Aldrich, UK 
CellTracker™ Green CMFDA Dye ThermoFisher Scientific, 
USA 
Corning® Collagen I, Rat Tail Corning, USA 
Coverslips 13mm Scientific Laboratories 
Supplies 
Cytoskeleton phospho antibody array Full moon biosystems, USA 
DH5α™ competent Escherichia coli (E.coli) cells Invitrogen, Uk 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, UK 
Dithiothreitol (DTT) Sigma-Aldrich, UK 
Dulbecco's Modified Eagle's Medium 
(DMEM) (5x) 
PAA, UK 
Doxycycline hyclate Sigma-Aldrich, UK 
DMEM Sigma-Aldrich, UK 





Epidermal growth factor (EGF) ThermoFisher Scientific, 
USA 
Ethanol BDH Laboratory Supplies, 
UK 
Ethyl 3-aminobenzoate methanesulfonate (MS222) Sigma-Aldrich, UK 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, UK 
Fibronectin Sigma-Aldrich, UK 
FluorSave™ Reagent Calbiochem, UK 
Foetal bovine serum (FBS) Gibco®, Invitrogen, UK 
Gel Cassettes Invitrogen, UK 
Gel loading dye (6x) New England Biolabs, UK 
Glycerol Sigma-Aldrich, UK 
Glycine Sigma-Aldrich, UK 
Hank's balanced salts solution Sigma-Aldrich, UK 
Hydrochloric acid (HCl) VWR International, UK 
Hepatocyte growth factor (HGF) PeproTech, UK 
IPA-3 Sigma-Aldrich, UK 
Kanamycin Invitrogen, UK 
Leupeptin Sigma-Aldrich, UK 
Low melting point agarose Invitrogen, UK 
Luria-Bertani (LB) Agar Sigma-Aldrich, UK 
Luria-Bertani (LB) broth tablets Sigma-Aldrich, UK 
Magnesium chloride (MgCl2) Sigma-Aldrich, UK 
Methanol VWR International, UK 
Methylene blue ThermoFisher Scientific, 
USA 
Milk powder Marvel, UK 
Nitrocellulose membrane PerkinElmer, UK 
Nonidet P-40 Sigma-Aldrich, UK 
N-Phenylthiourea (PTU) Sigma-Aldrich, UK 
OptiMEM Invitrogen, UK 
Paraformaldehyde (PFA) Sigma-Aldrich, UK 
Penicillin-streptomycin  Sigma-Aldrich, UK 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, UK 
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Phosphate buffered solution (PBS) tablets Oxoid Limited, UK 
Pierce™ ECL western blotting substrate ThermoFisher Scientific, 
USA 
Polybrene Sigma-Aldrich, UK 
Polyvinylpyrrolidone solution (PVP) Sigma-Aldrich, UK 
Potassium Chloride (KCl) Sigma-Aldrich, UK 
Precision Plus Protein™ dual color standards Bio-Rad, UK 
PureLink® HiPure plasmid maxiprep kit Invitrogen, UK 
Puromycin Sigma-Aldrich, UK 
Rapamycin Calbiochem, UK 
Rhodamine Phalloidin ThermoFisher Scientific, 
USA 
Roswell Park Memorial Institute (RPMI)-1640 medium Sigma-Aldrich, UK 
Sodium chloride (NaCl) Sigma-Aldrich, UK 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, UK 
Sodium fluoride (NaF) Alfa Aesar, UK 
Sodium hydroxide (NaOH) Sigma-Aldrich, UK 
Sodium orthovanadate (Na3VO4) New England Biolabs, UK 
Sodium pyrophosphate (Na4O7P2) BDH Chemicals, UK 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, UK 
Tris-base Sigma-Aldrich, UK 
Triton X-100 VWR International, UK 
Trypsin Gibco®, Invitrogen, UK 
Tween® 20 VWR International, UK 
ViaFect™ transfection reagent Promega, UK 
Virkon Powder Disinfectant DuPont, USA 
X-ray film Scientific Laboratories 
Supplies 
Zebrafish channel device MMB Foundry, USA 
Table 2.1 General materials 
2.1.2 Buffers and solutions 
Buffer/solution Composition 
Blocking solution 5% w/v milk powder or 5% w/v BSA in tris buffered 
saline (TBS)-tween (TBST) 
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Cell lysis buffer 0.5% NP-40, 30mM Na4O7P2, 50mM Tris-HCl pH7.6, 
150mM NaCl, 0.1mM EDTA, 1mM DTT, 10µg/ml 
leupeptin, 1µg/ml aprotinin, 10mM PMSF, 10mM 
NaF, 1mM Na3VO4 
E3 Media 5mM NaCl, 0.17mM KCl, 0.44mM CaCl2, 0.68mM 
MgSO4 in H2O 
FACS buffer 1% FBS, 1mM EDTA, 25mM HEPES in PBS-/- 
Gel sample buffer (6x) 375mM Tris-HCl pH 6.8, 10% w/v SDS, 30% v/v 
glycerol, 6% β-mercaptoethanol, 0.2% w/v 
bromophenol blue 
SDS-PAGE running buffer (10x) 250mM tris-base, 1.92M glycine, 1% w/v SDS 
SDS-PAGE transfer buffer (10x) 250mM tris-base. 1.92M glycine 
Stripping buffer 25mM glycine pH2, 1% w/v SDS 
TBST 25mM tris-HCl pH7.6, 50mM NaCl, 0.1% v/v tween 
20 
Type I Collagen mix 1.5mg/ml type I collagen, 20% 5X DMEM 
(containing 10% FBS) and 1% 1mM NaOH in sterile 
H2O 
Table 2.2 Buffers and solutions 
2.1.3 Primary antibodies 
Antibody Species Company Dilution for 
WB 
GAPDH Mouse Santa Cruz Biotechnology 1:5000 
PAK1 Rabbit Cell Signalling Technology 1:1000 
Phospho-PAK1/PAK2 
(Thr423/Thr402) 
Rabbit Cell Signalling Technology 1:1000 
Phospho- LIMK1/2 
(Thr508/Thr505) 
Rabbit Cell Signalling Technology 1:1000 
LIMK1 Mouse BD Transductions 
Laboratories 
1:1000 
LIMK2 Rabbit Cell Signalling Technology 1:1000 
Phospho-CRKII (Tyr221) Rabbit Cell Signalling Technology 1:1000 
FAK Rabbit Santa Cruz Biotechnology 1:1000 
Phospho-FAK (Ser910) Rabbit ThermoFisher Scientific 1:1000 
Vinculin Mouse Sigma-Aldrich 1:5000 
ERK1/2 (p44/42 MAPK) Rabbit Cell Signalling Technology 1:1000 
Phospho-ERK1/2 site (p44/42 
MAPK) (Thr202/Tyr204) 
Rabbit Cell Signalling Technology 1:1000 
ERK3 (MAPK6) Mouse Abnova 1:1000 
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Phospho-ERK3 (MAPK6) (Ser189) Sheep An in-house antibody 
kindly gifted by Professor 
Ole Morten Seternes, 
University of Tromsø, 
Norway 
1:1000 
Table 2.3 Primary antibodies used 
2.1.4 Secondary antibodies 
Antibody Species Company Dilution for 
WB 
Dilution for IF 
HRP conjugated anti-
mouse 
Goat DAKO 1:2000 - 
HRP conjugated anti-rabbit Goat DAKO 1:2000 - 
HPR conjugated anti-sheep Donkey R&D systems 1:2000 - 
Alexa Fluor® 488 Phalloidin - Invitrogen - 1:300 
Rhodamine phalloidin - Invitrogen - 1:1000 
Table 2.4 Secondary antibodies used 
2.1.5 shRNA sequences 
shRNA Target Sequence (5’-3’) Company 





ThermoFisher Scientific, UK 
(RHS4346) 





ThermoFisher Scientific, UK 
(V2LHS_152618) 





ThermoFisher Scientific, UK 
(V2LMM_68590) 
Table 2.5 shRNA constructs used 
2.1.6 CRIPSPR constructs 
CRISPR Target Sequence (5’-3’) Company 
PAK1_105909 TTATTTGACATTGTCACCAC Horizon Discovery 
PAK1_105910 GCTGGTATTTCTCATCGGAG Horizon Discovery 
PAK1_105911 GGTTCCAGCATCTTTGCTGC Horizon Discovery 
PAK1_105912 GAGGCAGAGGTTTAGAACCA Horizon Discovery 
PAK1_105913 TTATTTGCTGCAAGAGAAAC Horizon Discovery 



















Figure 2.1 Schematic diagram of CRISPR constructs. The plasmid DNA for the CRISPR-Cas9 
constructs. Detailed are the GFP tag, kanamycin resistance gene and guide RNA scaffold are 







Figure 2.2 Schematic diagram of PAK1 CRISPR target sites on the PAK1 gene. The 5’UTR (green), 
exons (orange), introns (yellow) and 3’UTR (grey) of the PAK1 gene are all shown. The target sites 
of the five PAK1 CRISPR constructs are shown in purple (PAK1_105909, 09 on figure), red 
(PAK1_105910, 10 on figure), turquoise (PAK1_105911, 11 on figure), pink (PAK1_105912, 12 on 


















2.2.1 Transformation of competent E.coli cells 
DH5α™ competent E.coli cells were removed from the -80°C freezer and thawed on ice. 
2ng of the required DNA plasmid was added to 20µl of competent cells and incubated on 
ice for 30 minutes. The cells were then heat shocked for 30 seconds in a 42°C water bath 
and returned to ice for two minutes. 500µl of warm LB broth was added to the cells which 
were then shaken at 225rpm for one hour at 37°C. 100µl of the transformed bacteria was 
spread on an LB agar plate containing appropriate antibiotic before the plates were 
inverted and incubated at 37°C overnight. The following morning a single colony was 
picked from the agar plate using a sterile pipette tip. The colony was grown in 200ml of LB 
broth containing the appropriate selection antibiotic for 24 hours. The following day a 
small amount of the bacterial culture was used to make a glycerol stock and the rest was 
used to purify the plasmid DNA. 
 
2.2.2 DNA plasmid purification  
Isolation and purification of the plasmid DNA from the E.coli cultures was performed using 
the Invitrogen PureLink® HiPure plasmid maxiprep kit according to the manufacturers’ 
protocol. The DNA was then ruspended in TE buffer and the DNA concentration was 
measured in ng/µl using a nano-drop. Purified DNA plasmids were stored at -20°C. 
 
2.2.3 Cell culture 
All cell lines were kept at 37°C with 5% atmospheric CO2 in a humidified tissue culture 
incubator (referred to as 37°C from here on). Cells were passaged regularly to ensure they 
did not reach confluency. To passage cells, the growth media was aspirated off and the 
cells were washed with phosphate buffered saline (PBS). Cells were then incubated with 
trypsin/EDTA at 37°C for five minutes to detach them from the flask/plate. Once detached, 
growth media was added to deactivate the trypsin before the cell suspension was 
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centrifuged at 1200rpm in an Eppendorf 5702 centrifuge with a A-8-17 rotor for four 
minutes to pellet the cells. The cell pellet was then resuspended in an appropriate volume 
of growth media and cells were then seeded at an appropriate density and dilutions into 
the plates and flasks required.  
Human embryonic kidney HEK293 cells, human pancreas adenocarcinoma PaTu-8988t 
cells and PaTu-8902 cells and human breast cancer MDA-MB-231 cells were obtained from 
Claire Wells, King’s College London and grown in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% v/v FBS, 100U/ml penicillin and 100µg/ml streptomycin. 
The media of MDA-MB-231 cells with PAK1 knockdown (sh1 and sh2 cells) and control 
cells were supplemented with 1µg/ml puromycin to select for cells containing the sh 
constructs (Table 2.5).  
Human prostate cancer PC3 cells were obtained from Claire Wells, King’s College London 
and grown in Roswell Park Memorial Institute (RPMI) 1640 supplemented with 10% v/v 
FBS, 100U/ml penicillin and 100µg/ml streptomycin. Human pancreatic cancer AsPC-1 
cells were obtained from Dr Stéphanie Kermorgant, Barts Cancer Institute and grown in 
RPMI 1640 supplemented with 10% v/v FBS, 100U/ml penicillin and 100µg/ml 
streptomycin. BT-549 cells were obtained from Dr Phillippe Chavrier, Centre de Recherche 
Institut Curie and were grown in RPMI 1640 supplemented with 10% v/v FBS, 100U/ml 
penicillin, 100µg/ml streptomycin and 10µg/ml insulin.  
Human breast cancer MDA-MB-231 cells (UNC-WT) and MDA-MB-231 stably expressing a 
Rap-PAK1 construct (S44) cells were obtained from Dr Klaus Hahn, University of North 
Carolina. The UNC-231 cells were grown in DMEM supplemented with 10% v/v FBS and 
1mM penicillin-streptomycin. The S44 cells were also grown in this media but additionally 
supplemented with 1µg/ml puromycin to select for the cells containing the Rap-PAK1 
construct and 10µg/ml doxycycline as the Rap-PAK1 construct operates as a Tet-off 
system. Two days before using the S44 cells in an experiment the cells were passaged, as 
written above, and media containing no doxycycline was added to the cells. Six hours after 
passaging the media was aspirated off, cells were washed with PBS and fresh media 
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containing no doxycycline was added to ensure that doxycycline was not present in the 
media thus allowing the Rap-PAK1 construct to be expressed.  
 
2.2.4 Cell storage and recovery 
To recover cells, cryovials, kept in the liquid nitrogen, were place in a 37°C water bath and 
allowed to thaw. Growth medium was added to the cell suspension which was then 
centrifuged for four minutes at 1200 rpm using an Eppendorf 5702 centrifuge with a A-8-
17 rotor. Cells were then resuspended in fresh growth medium and seeded into a flask or 
plate. The medium was changed the next day. 
To store cells, they were passaged as normal but resuspended in 90% FBS and 10% DMSO 
instead of normal growth medium. The cell solution was then transferred into cyrovials 
and placed into a cyro-freezing box in a -80°C freezer to ensure slow freezing. The vials 
were then transferred to liquid nitrogen at a later date for long term storage.  
 
2.2.5 Transfection of HEK293 with calcium phosphate 
HEK293 cells were seeded in a 2cm tissue culture dish at a density of 1 x 105 cells/ml and 
incubated overnight at 37°C. The following day the media was removed and replaced with 
fresh media. The transfection mixes are described in table 2.7.  
   2cm tissue culture dish (2ml) 
Tube A 6µl 2M CaCl2 (final concentration 60mM) 
4µg plasmid DNA 
Make up to 60µl with sterile H2O 
Tube B 60µl HEPES buffered saline 
Table 2.7 Calcium phosphate kit transfection mix 
Once prepared, tube A was added to tube B with aeration and left at room temperature 
for 30 minutes. The transfection mix was then added drop wise onto the cells which were 
then left at 37°C. The following day fresh media was replenished. Cells were then left for 
a further 48 hours before being harvested. 
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2.2.6 Transfection of MDA-MB-231 with viafect 
MDA-MB-231 cells were seeded in a 10cm plate at density of 1 x 105 cells/ml and 
incubated overnight at 37°C. The following day the media was removed and replaced with 
fresh media. The transfection mixes are described in table 2.8. 




Table 2.8 Viafect transfection mix 
Once prepared the transfection mix was incubated at room temperature for 17 minutes 
before being added drop wise onto the cells. The cells were then incubated for 24 hours 
at 37°C before the media was changed. The cells were then left for a further 24 hours at 
37°C before being harvested.  
 
2.2.7 Generation of stable fluorescent LifeAct cells 
Lentiviral vectors containing LifeAct-RFP was kindly gifted by Prof Maddy Parsons, King’s 
College London. The virus was packaged and harvested by Dr Jeremy Carlton. MDA-MB-
231 cells were plated at an appropriate density in a 6 well plate and kept at 37°C for 24 
hours. The following day fresh media was replenished and the viral construct was added 
drop wise to the media with 0.8 µg/ml polybrene. 24 hours later the media was 
replenished again. Cells were then passaged, as described in 2.2.3, four times in the virus 
tissue culture room before moving to the normal tissue culture room. Virus waste was left 
in 10% virkon for 24 hours before being disposed of. The virally infected cells subject to 
fluorescence-activated cell sorting (FACS) (as described in 2.2.9) to ensure all cells were 




2.2.8 Single cell cloning  
To single cell clone a population of cells, the cells were passaged (as described in 2.2.3) 
and once resuspended in fresh growth media the cells were counted, and a series of 
dilutions were made to give a suspension where there was appropriately one cell for every 
100µl. To each well of a 96 well plate 100µl was added and incubated at 37°C for two 
weeks. After two weeks cells were screened at regular intervals to note in which wells a 
population of cells appeared to be growing from a single cell. When a high enough 
confluency was reached cells were passaged and moved to a 24 well plate, then a 6 well 
plate and then finally a T25 flask. Cells were the frozen down (2.2.4) or lysed (2.2.10). 
 
2.2.9 Fluorescence-activated cell sorting 
To perform FACS, cells were passaged (as described in 2.2.3) but resuspended in FACS 
buffer (Table 2.2) instead of growth media. A cell suspension of 0.5 x 106 cells per ml was 
prepared and sorted with a BD FACSAriall SORP sorter using a 100nm nozzle, gated on 
forward and side scatter parameters, singlet discrimination and 488nm or 561nm lasers 
when selecting for GFP or RFP positive cells respectively. Doublets were excluded by FSC 
area vs FCS height. The selected cells were then placed in a suitable plate or flash 
depending on cell number and allowed to recover in growth media in a 37°C incubator. 
FACS was performed by Yasmin Sfy. 
 
2.2.10 Cell lysis 
Cells were seeded at an appropriate density in 6 well plates. Cells were washed twice with 
PBS and then 100µl of cell lysis buffer (Table 2.2) was added to each well for five minutes 
whilst the cells were placed on a rocking table on ice. Cells were then scraped off and 
pipetted into eppendorf tubes. The tubes were then centrifuged for ten minutes at 4°C at 
13,0000xg. The supernatant was then pipetted off and placed in a clean eppendorf. 20µl 
of 6x gel sample buffer (Table 2.2) was added and the eppendorf were boiled for five 




2.2.11 Gel electrophoresis and immunoblotting 
Lysates were boiled and loaded onto 10% acrylamide gels. Proteins were separated by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) at 130V for one 
and a half hours in 1x running buffer (Table 2.2). The proteins were then transferred onto 
a nitrocellulose membrane for one hour at 100V in 1x transfer buffer (Table 2.2). The 
membranes were the blocked for one hour at room temperature in either 5% milk in TBST 
or 5% BSA in TBST. The membranes were then placed in an appropriately diluted primary 
antibody (Table 2.3) in the same solution as used for blocking and placed on a tube roller 
over night at 4°C. The following day the membranes were washed three times in TBST 
(Table 2.2). They were then placed in the appropriately diluted secondary antibody (Table 
2.4) in the same solution as used for blocking for one hour at room temperature. The 
membranes were then washed three times in TBST. The probed proteins were the 
visualised using Pierce™ ECL western blotting substrate.  
 
2.2.12 Stripping nitrocellulose membranes  
Where appropriate, membranes were re-probed. To strip the membrane mild stripping 
buffer was used. Membranes were placed in this buffer two times for 15 minutes each 
time on a rocking table. The membranes were then washed in PBS ready to be blocked 
and re-probed with an appropriate primary antibody (as described in 2.2.11).  
 
2.2.13 Densitometry  
ImageJ was used to perform densitometry analysis on protein bands. A mean grey value 
was attributed to each band based on its intensity. The mean grey values were then 
normalised to background noise and the loading control used for that experiment, and 




2.2.14 Coverslip preparation 
13mm coverslips were acid treated to prepare them for immunofluorescence. The 
coverslips were placed in a beaker containing 40% of 70% ethanol and 60% 1M 
hydrochloric acid (HCl) for 24 hours. This solution was then replaced with dH2O which was 
then boiled. The coverslips were the rinsed in dH2O six times before being placed on 
whatman paper to dry. The coverslips were then transferred into a glass bottle and 
autoclaved to complete sterilisation.  
 
2.2.15 Collagen coating of coverslips 
Coverslips were placed in a desired plate. Type I collagen was diluted to 50 µg/ml in filter 
sterilised 0.02M glacial acetic acid (GAA). This solution was added to the coverslips and 
incubated for 60 minutes at room temperate. The collagen solution was removed, and the 
coverslips were washed three times with PBS. Cells were then seeded onto the coated 
coverslips.   
 
2.2.16 Fibronectin coating of coverslips 
Coverslips were placed in a desired plate and 10µg/ml human fibronectin solution in PBS 
was added. The plate was then placed in a 37°C incubator for 30 minutes. The fibronectin 
solution was removed and the coverslips were washed three times with PBS. Cells were 
then seeded onto the coated coverslips.   
 
2.2.17 Immunofluorescent staining and imaging 
Immunofluorescent staining was performed on cells seeded at an appropriate density on 
either glass, collagen coated or fibronectin coated coverslips. The coverslips were washed 
three times in PBS before being fixed in 4% paraformaldehyde (PFA) for 20 minutes at 
room temperature. For inhibitor experiments the cells were incubated with a final 
concentration IPA-3 or DMSO of 1µM for two, four or six hours prior to fixation. Once 
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fixed, the cells were washed a further three times and incubated in 0.2% X-triton for five 
minutes to permeabilised the cell membrane. The cells were then washed a further three 
times before being incubated in PBS containing phalloidin and DAPI at appropriate 
concentrations for 60 minutes in the dark. Cells were then washed a further two times in 
PBS and twice in ddH2O.  The coverslips were then mounted onto glass slides using 
FluroSave and left in the dark at room temperature overnight. The slides were stored at 
4°C. Coverslips were imaged using an Olympus IX71 microscope with either Image ProPlus 
AMS software or micromanager2.0beta depending on the camera installed at the time of 
imaging. 
 
2.2.18 Image processing and cell morphology analysis 
Images were opened in ImageJ. Cells were manually drawn around and parameters such 
as cell area and perimeter were measured for each cell.  
 
2.2.19 2D migration random migration assay and analysis  
Cells were seeded at an appropriate density in full growth medium on 50µg/ml type I 
collagen six well plate and placed in a 37°C incubator overnight. The next day the medium 
was replaced with 2ml of fresh medium containing 40µl of HEPES buffer, and where 
appropriate IPA-3 or DMSO was added to give a final concentration of 1µM two hours 
prior to the start of imaging. The plate was then sealed with parafilm and images were 
taken every five minutes for 16 hours at 37°C using an Olympus IX71 microscope and 
Image ProPlus AMS software. The images were extracted and saved as AVI files. These 
were then opened in ImageJ where the manual tracking plugin in was used to map both X 
and Y coordinates of a cell in each frame. This data was then analysed in Ibidi Chemotaxis 




2.2.20 Spheroid assay and analysis 
Spheroids were made by seeding 1000 cells in 100µl of full growth medium into a Corning 
black walled 96-well clear black round bottom ultra-low attachment spheroid microplate. 
The plate was then kept in a 37°C incubator for five days. After the five days the medium 
was removed and replaced with type I collagen mix (Table 2.2). The plate was the placed 
back in the incubator for two hours to allow the collagen to set. 100µl of full growth 
medium was then gently added on top of the collagen, for the inhibitor experiments either 
5µM of IPA-3 or DMSO was added to the media. The spheroids were then imaged using 
an Olympus IX71 microscope and micromanager2.0beta software. The plate was then 
placed back in the incubator for 24 hours before the spheroids were imaged again. 
Spheroid images were analysed in ImageJ. The initial and final spheroid sizes were 
measured and the number of cells that invaded outside of a defined area were counted 
using the ImageJ cell counter function.  
 
2.2.21 Zebrafish embryo maintenance   
All zebrafish work completed was approved by the King’s College Ethical Review 
committee and performed under the UK Home Office licence PPL 70/7912.  
Zebrafish were collected from zebrafish facility and separated into multiple 10cm dishes 
with 1X E3 media with 0.0002% methylene blue and kept at 28°C. At 6-8 hours post 
fertilisation (hpf) any debris and unfertilised cells were removed from the dishes. At 1-day 
post fertilisation the chorion of the zebrafish was removed from each embryo to allow the 
embryos to straighten during development. At 6dpf or the end of an experiment, 
whichever was sooner, embryos were culled by exposure to an anaesthetic overdose of 




2.2.22 Zebrafish yolk invasion assay and imaging 
Needles were pulled using a P-87 Flaming/Brown Micropipette Puller. The glass capillaries 
were pulled at both ends away from the heating element to create two fine needles.   
The AsPC-1 cells were washed with PBS and incubated at 37°C for 10 minutes in cell 
dissociation buffer. Once detached from the flask media was added and the cells were 
centrifuged for four minutes at 1200rpm using an Eppendorf 5702 centrifuge with a A-8-
17 rotor to form a cell pellet. The pellet was then resuspended and incubated in a mix of 
PBS and CellTracker™ Green CMFDA Dye (final concentration 5µM) for 30 minutes at 37°C. 
The cells were then centrifuged again for four minutes at 1200rpm using an Eppendorf 
5702 centrifuge with a A-8-17 rotor. The cell pellet was then resuspended in PBS-/- and a 
50µl solution containing 2.1x107 cells/ml and 10% PVP. The cells were stimulated with 
50ng/ml HGF prior to injection.  
The virally infected MDA-MB-231 cells were and incubated at 37°C for 10 minutes in cell 
dissociation buffer. Once detached from the flask media was added and the cells were 
centrifuged for four minutes at 1200rpm using an Eppendorf 5702 centrifuge with a A-8-
17 rotor to form a cell pellet. The cell pellet was then resuspended in PBS-/- and a 50µl 
solution containing either 1.6 x 104cells/µl,  2.1 x 104cells/µl or 3.2 x 104cells/µl  and 10% 
PVP. The cells were stimulated with 50ng/ml EGF prior to injection.  
Zebrafish embryos at 2dpf were placed in E3 media containing 3.5mM of MS222 and 1% 
penicillin-streptomycin. They were then placed in a V shape grooved 2% agarose (in H2O) 
mould. The cells were loaded into the glass capillary needle and approximately 200-500 
cells were injected into the yolk sac of the zebrafish using a Nikon SMZ-U zoom 1:10 
Picospritzer II microinjection station. Embryos were then placed back in E3 media 
containing 3.5mM of MS222 and 1% penicillin-streptomycin and allowed recover for one 
hour at 28°C. They were then transferred to 33°C for the remainder of the experiment.  
For AsPC-1, two hours post injection embryos which lacked a tumour mass in the yolk sac 
or had cells outside of the yolk sac were removed and humanely killed using 15mM MS222. 
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The percentage of embryos with tail fish invasion was calculated 24 hours post injection. 
For MDA-MD-231 cells, 24 hours post injection embryos which lacked a tumour mass in 
the yolk sac or had cells outside of the yolk sac were removed and humanely killed using 
15mM MS222. For inhibitor experiments either IPA-3 or DMSO was added to the post 
injected water at a final concentration of 5µM until the end of the experiment. The 
percentage of embryos with tail fish invasion was calculated four days post injection (dpi). 
They embryos were then humanely killed using 15mM MS222.  
2.2.23 Rapamycin experiments 
For the rapamycin morphology experiments an appropriate number of cells were seeded 
onto glass, collagen or fibronectin coated coverslips in full growth medium and kept in a 
37°C incubator for 24 hours. Rapamycin in FBS free medium was added to the cells at 0, 5, 
20 and 60 minutes so the final concentration of rapamycin was 500nM. At these time 
points cells were fixed and stained (as described in 2.2.17).  
For the rapamycin western experiments an appropriate number of cells were seeded onto 
collagen coated six well plates in full growth medium and kept in a 37°C incubator for 24 
hours. Rapamycin in FBS free medium was added to the cells at 0, 5, 20 and 60 minutes so 
the final concentration of rapamycin was 500nM. At these time points cells were lysed (as 
described in 2.2.10).  
 
2.2.24 Cytoskeleton phospho antibody array  
1 X 106 cells were seeded on two collagen coated 10cm tissue culture plates. Rapamycin 
in FBS free medium was added to one plate, the final concentration of rapamycin was 
500nm. The same volume of in FBS free medium not containing rapamycin was added to 
the other plate. Both plates were then incubated at 37°C for five minutes. Cells were lysed 
and the Full Moon BioSystems cytoskeleton phospho antibody array was performed 
according to the manufacturer’s protocol and returned to Full Moon BioSystems to be 
scanned and imaged.  
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Once received the phosphoarray images were analysed using ImageJ. Each circle was 
attributed a mean grey value score which was then normalised to background noise and 
the loading marker. A value was calculated for each protein on the array and the fold 
change in signal for each protein was calculated between the plus and minus rapamycin 
conditions.    
2.2.25 Statistical analysis 
GraphPad Prism was used to perform an unpaired t-test on datasets generated from three 
independent experiments. A P value of ≤0.05 (95% confidence interval), ≤0.01 (99% 
confidence interval) and ≤0.001 (99.9% confidence interval) are indicated by *, ** and *** 
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Chapter 3 The effect of PAK1 perturbation on cell 
morphology and migration   
3.1 Introduction  
Cells remodel their cytoskeletons to regulate cell movement and migration (Yilmaz and 
Christofori, 2009). One of the key family of proteins involved in this process are the Rho 
GTPases (Vega and Ridley, 2008). Cdc42 and Rac1, two of the most widely studied Rho 
GTPases, are key regulators of cell motility due to their ability to control the 
polymerisation, depolymerisation and branching of actin filaments (Vega and Ridley, 
2008). The p21 activated kinase (PAK) family are the most well characterised downstream 
effectors of Cdc42 and Rac1 (Bishop and Hall, 2000). 
The PAKs are a family of serine/threonine kinases that are involved in a wide range of 
cellular processes, many of which are important in cancer (King et al., 2014, Radu et al., 
2014). There are six PAK family members which are divided into two groups – PAK1-3 
(group I) and PAK4-6 (group II) – based on similarities in their sequences, domains and 
regulation (Arias-Romero and Chernoff, 2008). The involvement of the PAK family in 
cancer formation, progression and metastasis has been widely noted due to their roles in 
cellular processes such as proliferation, apoptosis and cell migration (King et al., 2014). 
PAK1 is the member of the PAK family which is most studied and associated with cancer.  
PAK1 has been shown to play a role in, but not limited to, bladder, colorectal, endometrial, 
kidney, liver, lung, melanoma, prostate and ovarian cancers (King et al., 2014). A multitude 
of studies have also demonstrated PAK1 contributes to breast cancer formation, 
development and metastasis (King et al., 2014).  
PAK1 is implicated in breast cancer due to its overexpression, genomic amplification and 
increased phosphorylation (Balasenthil et al., 2004, Holm et al., 2006, Bostner et al., 2007, 
Stofega et al., 2004, Vadlamudi et al., 2000). PAK1 has also been linked to tamoxifen 
resistance in the treatment of ER positive breast cancers (Holm et al., 2006).   
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As PAK1 is a downstream effector of Cdc42 and Rac1 and is heavily involved in many 
cancer types, it is no surprise PAK1 has been heavily linked to cell migration of both 
cancerous and non-cancerous cell types. Active PAK1 has been shown to localise to leading 
edge of motile fibroblasts (Sells et al., 2000) and to lamellipodia and sites of membrane 
ruffling (Dharmawardhane et al., 1997).  
Studies in downstream signalling from PAK1 also support an importance for PAK1 in cell 
motility; this is largely due to PAK1’s ability to alter the cells cytoskeleton. PAK1 can 
phosphorylate LIMK downstream of Cdc42 and Rac1 which induces cytoskeletal changes 
(Edwards et al., 1999). Once phosphorylated, LIMK1 is able to phosphorylate cofilin, 
resulting in the inhibition of its actin severing functions. This leads to growth of actin fibres 
which can form plasma membrane protrusions (Arber et al., 1998, Yang et al., 1998).  
 
PAK1 also plays a role Akt signalling and cell migration (Huynh et al., 2010). When activated 
by Rac1, PAK1 acts as a scaffold to induce Akt stimulation via PDK1. PAK1 is able to recruit 
Akt to the membrane in motile cells (Higuchi et al., 2008) and can enhance migration and 
invasion of colon cancer cells (Huynh et al., 2010).  
 
PAK1 can also influence the cytoskeleton by interacting with actin binding proteins. PAK1 
induces membrane ruffling when it interacts with filamin A (Vadlamudi et al., 2002) and 
can promote the formation of the Arp2/3 complex by phosphorylating the p41-Arc- a 
subunit, this results in enhanced actin polymerisation in breast cancer cell migration 
(Vadlamudi et al., 2004). Whilst the role of PAK1 in cell migration has been studied, the 
requirement of PAK1 in MDA-MB-231 cell migration has not previously been assessed by 
depletion studies. In addition to this, very little is known about the role of PAK1 in 
spreading, and the specific role of PAK1 in MDA-MB-231 cell morphology is currently 
unknown. 
 
Interestingly, recent studies have highlighted the PAK family also exhibit kinase 
independent functions (Wang et al., 2013, Dart et al., 2015, Thullberg et al., 2007). As PAK1 
is heavily implicated in breast cancer and plays an important role in cell motility, this 
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chapter aims to investigate the role of PAK1 and its kinase activity on breast cancer cell 



















3.2 Results  
3.2.1 PAK1 is expressed in breast, pancreatic and prostate cancer cell lines 
As PAK1 is reportedly expressed in a wide range of cancers (Kichina et al., 2010), a panel 
of cancer cell lines were studied to determine their level of PAK1 expression. Two breast 
cancer cell lines (MDA-MB-231 and BT-549 cells), a prostate cancer cell line (PC3) and two 
pancreatic cancer cell lines (PaTu-8902 and PaTu-8988T) were assessed.  
Both breast cancer cell lines are from TNBC. The MDA-MB-231 cell line was originally 
isolated from a pleural effusion from a breast cancer patient suffering widespread 
metastasis (Cailleau et al., 1974). BT-549 cells are derived from the primary tumour of an 
invasive ductal carcinoma (Littlewood-Evans et al., 1997). PC3 cells were isolated from a 
bone metastasis from a patient suffering from prostatic adenocarcinoma (Kaighn et al., 
1979). PaTu-8902 cells were derived from a primary grade II pancreatic ductal 
adenocarcinoma (Elsasser et al., 1993). The PaTu-8988T cells were isolated from a liver 
metastasis from a patient suffering with pancreatic adenocarcinoma (Elsasser et al., 1992). 
These cell lines were selected as they all exhibit mesenchymal cell migration, a mode of 
migration where PAK1’s importance has been previously reported (Al-Azayzih et al., 2015).  
All five cancer cell lines assessed express PAK1 (Figure 3.1). PAK1 expression was highest 
in the PaTu-8988T cells and MDA-MB-231 cells, these both being cell lines derived from 
metastatic sites. BT-549, PC3 and PaTu-8902 cells all have a lower level of PAK1 
expression. The MDA-MB-231 cell line has significantly higher PAK1 expression than the 






















Figure 3.1 PAK1 expression in cancer cell lines.(A) Cell lysates from breast (MDA-MB231 and BT-
549), prostate (PC3) and pancreatic (PaTu-8092 and PaTu-8988T) cancer cells were probed for 
PAK1. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. (B) 
Densitometric analysis on ImageJ was used to compare the expression levels of PAK1, normalised 
to the loading control and background noise. Error bars represent the SEM for three independent 
experiments. Statistical analysis was carried out using t-tests (** p<0.01, *** p<0.001). 
74 
 
3.2.2 Knockdown of PAK1 impacts cell morphology and migration 
Having confirmed the expression of PAK1 in MDA-MB-231 cells, the effect of reducing 
PAK1 expression levels on cell morphology and migration was investigated. To achieve this 
objective stable PAK1 depleted cell lines were generated using two different PAK1 specific 
short hairpin ribonucleic acid (shRNA) constructs. In parallel a control shRNA line was also 
generated. Analysis of cells lysates derived from these lines revealed a significant 
knockdown in PAK1 expression compared to the wild-type cells, with approximately a 45% 
and 70% reduction for sh1 and sh2 constructs respectively (Figure 3.2). No significant 
change of PAK1 expression in the control shRNA construct and wild-type cells was 
observed (Figure 3.2). These established MDA-MB-231 cell lines containing the sh1, sh2 
and control shRNA constructs alongside the wild-type untransfected control cells were 






























Figure 3.2 shRNA knockdown of PAK1 in MDA-MB-231 cells. Whole cell lysates were prepared 
from MDA-MB-231 cells transfected with two shRNA PAK1 constructs and an shRNA control 
construct. A wild-type untransfected control was also used. (A) Representative western blot 
indicating a knockdown of PAK1 expression with both PAK1 shRNA constructs (sh1 and sh2) but 
not the shRNA control (control) construct compared to the wild-type control. GADPH was used as 
the loading control. (B) Densitometric analysis on ImageJ was used to compare the expression 
levels of PAK1, normalised to the loading control and background noise. Error bars represent SEM 





The cells were characterised for changes in cell morphology and migration potential on 
type I collagen, as this is more physiologically relevant than plastic or glass.   
Differences in morphology following PAK1 knockdown could imply changes in a cell’s 
ability to migrate and invade. Morphological analysis revealed a significant decrease in cell 
spread area and perimeter for both shRNA PAK1 knockdown cell lines (sh1 and sh2) 
compared to wild-type cells (Figure 3.3). No significant difference in these measurements 





















Figure 3.3 Morphology of shRNA PAK1 knockdown MDA-MB-231 cells. (A) shRNA PAK1 knockdown 
cells (sh1 and sh2), shRNA control cells (control) and wild-type cells (WT) were seeded onto collagen 
coated coverslips, fixed and stained for DAPI and phalloidin. A GFP signal is used to confirm presence 
of the shRNA constructs. Cells were then subject to morphological analysis using ImageJ. The scale 
bar represents 10µm. (B and C) Graphical representation of cell area (B) and perimeter (C) for 
knockdown and control cells. Error bars represent SEM for three independent experiments, 30 cells 




The phenotypic morphology of cancer cells has been widely linked to their ability to 
migrate (Clark and Vignjevic, 2015). Having observed shRNA induced knockdown of PAK1 
in MDA-MB-231 cells causes a decrease in cell spread area (Figure 3.3), the cells ability to 
migrate was assessed. 
Cells depleted of PAK1 show a significantly reduced mean cell speed on type I collagen 




































Figure 3.4 2D migration of shRNA PAK1 knockdown MDA-MD-231 cells. (A) shRNA PAK1 
knockdown and control cells were seeded onto type I collagen and imaged for 16 hours. ImageJ was 
used to manually track the cells and cell speeds and plots were obtained using ibidi chemotaxis and 
migration tool.  (B) Graphical representation of shRNA PAK1 knockdown and control cells. Error bars 
represent SEM for three independent experiments, 20 cells per experiment. Statistical analysis was 
carried out using t-tests (*** p<0.001). 
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3.2.3 CRISPR of PAK1 impacts cell morphology and behaviour  
To complement shRNA knockdown of PAK1 an alternative approach to perturbing PAK1 
expression was attempted using CRISPR-Cas9 technology. Potential genomic alteration is 
produced when a short guide RNA (sgRNA) specific to a region of the target gene guides 
the Cas-9 deoxyribose nucleic acid (DNA) nuclease to the target site in the genome. Cas-9 
will then cleave the genomic DNA in site specific manner. Once damaged, the cell will 
repair the DNA by either non-homologous end joining (NHEJ) or homologous directed 
repair (HDR) which often lead to insertion or deletion mutations. These mutations are 
likely to cause a frame-shift or premature stop coding thus a functioning protein is not 
produced due to an alteration at the genomic level (Hsu et al., 2014).   
Five PAK1 CRISPR constructs were available from Horizon Discovery (Table 2.6). All five 
constructs target before or within exon two of the PAK1 gene (Figure 2.2). To validate and 
select the most efficient construct HEK293 cells were used as they have a high transfection 
efficiency which would result in an increased likelihood of a CRISPR event occurring.  It 
was not expected to see a total knockout of PAK1 in this experiment as not all cells would 
be transfected with the construct, and a CRISPR event would not take place in all the 
transfected cells, therefore the reduction in PAK1 expression was used as a measure of 
efficiency for the different CRISPR constructs. The PAK1 expression level was assessed by 
western blotting. All CRISPR constructs, except for CRPISPR 13, show a significant 
knockdown of PAK1 expression compared to wild-type cells (Figure 3.5).  CRISPR 9 induced 
the greatest reduction in PAK1 expression (Figure 3.5) and was selected as the construct 
























Figure 3.5 Validation of PAK1 CRISPR constructs in HEK293 cells. Whole cell lysates were prepared 
from HEK293 cells transfected with different PAK1 CRISPR constructs (CRISPR 9-13). (A) 
Representative western blot indicating the level of PAK1 expression with each different CRISPR 
construct and the wild-type untransfected control. GADPH was used as the loading control. (B) 
Densitometric analysis on ImageJ was used to compare the expression levels of PAK1, normalised 
to the loading control and background noise. Error bars represent SEM for three independent 




To generate an MDA-MB-231 PAK1 knockout cell line a CRISPR protocol was designed 
(Figure 3.6). MDA-MB-231 cells were seeded onto dishes and transfected with the CRISPR 
9 construct. As the plasmid encoding the CRISPR sequence and Cas-9 contains a GFP tag 
(Figure 2.1), 48 hours after transfection the cells were FACS sorted to select GFP positive 
cells, thus ensuring all cells used from now on had been transfected with the plasmid. The 
cells were allowed to recover and were then single cell cloned to ensure, if a CRISPR event 
had occurred on all copies of the PAK1 gene, all cells within the population would have no 
PAK1 expression. The single cell clones were expanded and either cell lysates prepared for 
western blotting or DNA extraction was performed for polymerase chain reaction (PCR). 
PCR primers were designed to bind the genomic DNA over the target site of the CRISPR9 
construct. This would allow PCR amplicons of the PAK1 gene to be generated from 
unsuccessful CRISPR and wildtype clones but no PCR product would be generated from 
clones which had complete PAK1 knockout.  Unfortunately, despite multiple strategies 
and extensive optimisation of a PCR protocol, generation of specific amplicons without 
non-specific bands of the PAK1 gene on wildtype DNA was unsuccessful. Therefore, 
western blotting was used to identify any potential PAK1 knockout clones, which offers 
the advantage of direct identification of total knockout at the protein level. 
Lysates from 68 different single cell populations were subject to western blotting and 
probed for PAK1 to identify any clones with a loss of PAK1 expression.  
Western blots revealed cell populations with varying levels of PAK1 expression, as shown 
in the representative blot (Figure 3.7). Two single cell populations, 2.10 and 1.22 were 
identified as a potential PAK1 knockout cell population as no PAK1 band appeared on the 
western blot (Figure 3.7) despite prolonged exposure to autoradiographs. These two cell 
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Figure 3.6 Flow diagram of CRISPR protocol. A flow diagram explaining the steps used to develop 


















Figure 3.7 CRISPR screening using western blotting. Whole cell lysates were prepared from MDA-
MB-231 single cell populations transfected with PAK1 CRISPR construct, CRISPR9. A representative 
western blot indicating the level of PAK1 expression in eight different single cell populations. An 
untransfected wild-type cell population was also included.  GADPH was used as the loading control 
(n=1).   
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For both 1.22 and 2.10 cell clones, when first recovered into culture from liquid nitrogen 
at passage number zero (P+0), no PAK1 expression was detected in the cell lysates. Lysates 
were made after two weeks in culture at passage number four (P+4), after four weeks in 
culture at passage number eight (P+8) and after six weeks in culture at passage number 
12 (P+12). It was observed that as the cells were continuously cultured, PAK1 expression 
levels increased relative to their passage number (Figure 3.8).  Although PAK1 levels were 
now detectable, up to passage number eight (P+8) the 1.22 and 2.10 cell clones still had a 
significant reduction in PAK1 expression levels, with a 48% and 57% knockdown 
respectively, compared to the wild-type control.  (Figure 3.8). The initial aim of generating 
a complete PAK1 knockout MDA-MB-231 cell line was unsuccessful however two MDA-
MB-231 cell clones with a significantly reduced level of PAK1 had been generated provided 
the passaged number was less than eight.  
Thus clones 1.22 and 2.10 are PAK1 depleted and can be directly compared with the 





























Figure 3.8 PAK1 expression in CRISPR PAK1 knockdown cells. Whole cell lysates prepared from two 
different MDA-MB-231 cells clones, 1.22 and 2.10, which were previously identified as being a 
potential PAK1 knockout. (A and C) Representative western blots showing PAK1 expression of cell 
clones 1.22 and 2.10 respectively at different passage numbers. A wild-type control is also present, 
GAPDH was used as the loading control. (B and D) Densitometric analysis on ImageJ was used to 
compare the expression levels of PAK1 normalised to the loading control and background noise, in 
1.22 and 2.10 cell clones respectively. Error bars represent SEM for three independent experiments. 
Statistical analysis was carried out using t-tests (*** p<0.001). 
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Thus, as PAK1 reduction using shRNA showed a significant reduction in cell spread area 
(Figure 3.3) the CRISPR PAK1 knockdown cells area was quantified.  
CRISPR PAK1 knockdown cells, 1.22 and 2.10, and wild-type control cells were seeded on 
rat tail type I collagen coated coverslips, fixed and stained with DAPI and rhodamine 
phalloidin as before (Figure 3.3). Cells were then subject to morphology analysis in ImageJ. 
This analysis revealed a significant decrease in cell area and perimeter of both 1.22 and 
2.10, the CRISPR PAK1 knockdown cells, compared to the wild-type cells (Figure 3.9) 

































Figure 3.9 Morphology of CRISPR PAK1 knockdown MDA-MB-231 cells. (A) CRISPR PAK1 
knockdown cells (1.22 and 2.10) and wild-type cells (WT) were seeded onto collagen coated 
coverslips, fixed and stained for DAPI and phalloidin. Cells were then subject to morphological 
analysis using ImageJ. The scale bar represents 10µm. (B and C) Graphical representation of cell 
area (B) and perimeter (C) for knockdown and wild-type cells. Error bars represent SEM for three 






Both the CRISPR PAK1 knockdown cells and the shRNA PAK1 knockdown cells show a 
decreased in cell spread area compared to wild-type and control cells (Figure 3.3 and 3.9). 
Therefore, CRISPR PAK1 knockdown cells were assessed to examine if this change in 
morphology also caused a reduction in mean speed of cell migration, as seen in the shRNA 
PAK1 cells (Figure 3.4).  
The two CRISPR PAK1 knockdown cell populations show a significantly reduced mean cell 
speed compared to wild-type cells (Figure 3.10), consistent with the PAK1 shRNA 
































Figure 3.10 2D migration of CRISPR PAK1 knockdown MDA-MD-231 cells. (A) CRISPR PAK1 
knockdown and wild-type cells were seeded onto type I collagen and imaged for 16 hours. ImageJ 
was used to manually track the cells and cell speeds and plots were obtained using ibidi chemotaxis 
and migration tool.  (B) Graphical representation of CRISPR PAK1 knockdown and wild-type cells. 
Error bars represent SEM for three independent experiments, 20 cells per experiment. Statistical 
analysis was carried out using t-tests (*** p<0.001). 
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3.2.4 Pharmacological inhibition of PAK1 impacts cell morphology and 
migration 
Depleting PAK1 protein levels using shRNA and CRISPR technology results in a decrease in 
cell area and perimeter and a decrease in mean speed of cell migration. This highlights the 
importance that PAK1 plays in both cell morphology and migration. Whilst it is clear PAK1 
plays a role in the morphology and migration of MDA-MD-231 cells it was unclear if this 
was in a kinase dependent manner. It was therefore decided to further investigate 
whether these phenotypes were dependent on the kinase activity of PAK1. 
To explore the relationship between observed phenotypes in a PAK1 depleted background 
and kinase activity a widely employed PAK1 specific inhibitor was utilised. IPA-3 is a non-
ATP competitive inhibitor of PAK1 activation; it targets the autoregulatory mechanism 
PAK1 possesses by covalently binding to its regulatory domain (Deacon et al., 2008, Viaud 
and Peterson, 2009). If the morphological and migratory phenotype seen in knockdown 
PAK1 cells is due to a kinase dependent function of PAK1, the same phenotype should be 
observed with IPA-3 treated cells.  
To investigate the effects IPA-3 had on cell morphology, wild-type MDA-MB-231 cells were 
incubated with the inhibitor or a DMSO control for two, four or six hours. 1µM of IPA-3 
was used based of previous publications (Wang et al., 2016). Morphological analysis was 
then performed on the cells.  At all three-time points (two, four and six hours) IPA-3 
treated MDA-MD-231 cells showed a significant decrease in cell area and size compared 






























Figure 3.11 The effect of IPA-3 on MDA-MB-231 cell morphology. (A) Representative images of 
wild-type MDA-MB-231 cells when treated with IPA-3 and a DMSO control. Wild-type MDA-MD231 
cells were seeded onto collagen coated coverslips and incubated with IPA-3 or DMSO for two, four 
and six hours. Cells were then fixed and stained for DAPI and phalloidin. Cells were then subject to 
morphological analysis using ImageJ. The scale bar represents 10µm. (B, D and F) Graphical 
representation of cell area after incubation for two hours (B), four hours (D) and six hours (F). (C, E 
and G) Graphical representation of perimeter after incubation for two hours (C), four hours (E) and 
six hours (G). Error bars represent SEM for three independent experiments, 30 cells per experiment. 
Statistical analysis was carried out using t-tests (* p<0.05) 
93 
 
Pharmacological inhibition of PAK1 rendered the same morphological phenotype, a 
reduced cell spread area, as PAK1 knockdown studies. Therefore, 2D cell migration of 
MDA-MB-231 cells treated with the PAK1 kinase inhibitor was investigated to examine if 
pharmacological inhibition also caused the same phenotype compared to the previous 
PAK1 knockdown data.  
Wild-type MDA-MB-231 cells were incubated with IPA-3 or DMSO one hour prior to 
imaging. Cells treated with the IPA-3 inhibitor show a significantly reduced mean cell 
































Figure 3.12 The effect of IPA-3 on MDA-MB-231 cells in 2D migration. (A)  Wild-type MDA-MB-231 
cells were seeded onto type I collagen and incubated with IPA-3, DMSO or nothing. The cells were 
then imaged for 16 hours. ImageJ was used to manually track the cells and cell speeds and plots 
were obtained using ibidi chemotaxis and migration tool.  (B) Graphical representation of the mean 
speed of cell migration of wild-type cells alone or incubated with IPA-3 or a DMSO control. Error 
bars represent SEM for three independent experiments, 20 cells per experiment. Statistical analysis 
was carried out using t-tests (*** p<0.001). 
95 
 
3.3 Discussion  
It has been well established that PAK1 plays a role in cell migration and is overexpressed 
in many breast cancers (Radu et al., 2014). However, it is not clear to what extent PAK1 
has a role in influencing the morphology and migration of breast cancers, and whether 
this is a kinase dependent function. Establishing a role for PAK1 in breast cancer cell 
migration, if due to its kinase activity, could identify a new therapeutic target to prevent 
metastatic disease.  
First, PAK1 expression was confirmed in the various cancer cell types and the breast cancer 
cell line with the highest PAK1 expression was identified as MDA-MB-231 cells.  PAK1 
expression was detected in breast cancer cell lines, MDA-MB-231 and BT-549 cells (Figure 
3.1). This is not surprising as PAK1 has been widely detected in both breast cancer cell 
lines and breast cancer tissue staining, with studies suggesting up to 55% of breast cancers 
have PAK1 overexpression  (Balasenthil et al., 2004).  Staining of human breast cancer 
tissue has also implicated PAK1 as an important factor in breast cancer cell migration. High 
PAK1 expression has been associated with lymph node metastasis and correlated with 
poor prognosis (Ong et al., 2011) .  
Expression of PAK1 in both MDA-MB-231 and BT-549 cell lines have been previously 
reported (Zhan et al., 2017). MDA-MB-231 cells have been reported to express high levels 
of PAK1 when comparing them to other breast cancer cell lines. Ergun et al (2015) found 
that although all breast cancer cell lines assessed had PAK1 expression, MDA-MB-231 cells 
have the highest expression in PAK1 compared to four other breast cancer cell lines: 
SKBR3, MCF-7, HCC1500 and ZR-75-1. In this study the MDA-MB-231 cell line is shown to 
have a 2.1-fold increase in PAK1 expression compared with hTERT-HME1 cells, a human 
breast epithelial cell line (Ergun et al., 2015). It has also been shown that MDA-MB-231 
cells have a higher PAK1 expression level than the MCF-7 breast cancer cell line (Morimura 
and Takahashi, 2011).  Fewer studies regarding PAK1 in the BT-549 cell line have been 
published although previous expression has been noted (Zhan et al., 2017). In this chapter 
it is confirmed PAK1 is expressed in both MDA-MB-231 and BT-549 cells, in agreement 
96 
 
with existing literature, but also allows direct comparison of PAK1 expression between the 
two cell lines.  
PAK1 expression was also observed in PC3, PaTu-8988T and PaTu-8902 cells (Figure 3.1). 
PAK1 expression has previously been reported in PC3 cells (Al-Azayzih et al., 2015) and 
PaTu-8988T cells (King et al., 2017).  However, PAK1 expression has not been reported in 
the pancreatic cell line PaTu-8902, although PAK1 expression has been noted in other 
pancreatic cell lines (Jagadeeshan et al., 2015, King et al., 2017).  
Interestingly PAK1 knockdown using shRNA or CRISPR-Cas9 technology has not been 
reported in MDA-MB-231 cells.  Unfortunately, an MDA-MB-231 cell clone with complete 
PAK1 knockout was not generated. Whilst initially no PAK1 protein is detected, as the 
passage number increases PAK1 expression is detectable although at lower levels than 
wildtype cells (Figure 3.8). This is an interesting phenomenon as a CRISPR event occurs at 
the genomic level and therefore if completely successful re-expression of the targeted 
protein is not possible.  
The number of PAK1 alleles present in the MDA-MB-231 genome could influence the 
outcome of generating a complete PAK1 knockout. If MDA-MB-231 cells have an increased 
number of PAK1 alleles, all copies of the gene would need to be altered by CRISPR-Cas9 
technology, ensuring no PAK1 mRNA was transcribed, thus decreasing the likelihood of 
generating a full PAK1 knockout.  
PAK1 is located at 11q13.5 in the genome, a region that is commonly amplified in breast 
cancer (Ong et al., 2011, Bekri et al., 1997). More often associated with hormone receptor 
and HER2 positive tumours; amplification of the gene has been demonstrated in TNBC, 
with a mean copy number of 2.8 and a PAK1 amplicon frequency of 18% in TNBC tissue 
(Ong et al., 2011). Although genomic amplification of PAK1 in MDA-MB-231 cells has not 
been identified (Shadeo and Lam, 2006), the cells have a mean chromosome number 
ranging from 65-69 (Cailleau et al., 1974) with four copies of chromosome 11 compared 
to two in normal breast epithelial cells (Yoon et al., 2002). This, taken with the reported 
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high expression of PAK1 in MDA-MB-231 cells (Ergun et al., 2015) and findings in this 
chapter suggests increased expression due to aneuploidy of chromosome 11 in this cell 
line. 
Two potential theories could explain the re-expression of PAK1 in the MDA-MD-231 cell 
line. Firstly, as MDA-MB-231 cells are likely to have an increased number of PAK1 genes, 
due to aneuploidy of chromosome 11 (Yoon et al., 2002), there is a possibility not all PAK1 
genes were actively being expressed, i.e. - some were silenced. As PAK1 expression is 
detected at later passage numbers not all the copies of PAK1 were subject to alteration by 
CRISPR-Cas9 technology. If the active copies of PAK1 were altered by CRISPR-Cas9 so they 
no longer expressed PAK1 mRNA, other silenced copies which were unaffected by CRISPR-
Cas9 could be switched on to compensate for the loss of PAK1 expression. This could 
explain the absence of PAK1 expression initially but the return of expression to detectable 
levels as passage number increased.  To validate this theory sequencing of PAK1 in the 
MDA-MB-231 cells would be necessary.  
The second explanation relates to single cell cloning, performed manually, of the MDA-
MB-231 cells once FACS sorted. Cell populations grown from a single cell clone were 
identified in wells of a 96 well plate using a microscope. A successful PAK1 knockout cell 
when single cell cloned would produce a cell population completely lacking PAK1 
expression. However, if a cell population was falsely identified as originating from a single 
cell, i.e. - the cell population came from multiple cells, this could result in a mixed 
population of cells expressing different levels of PAK due to the success or failure of the 
CRISPR-Cas9 technology. If initially the PAK1 knockout cells grew quicker than the wildtype 
or knockdown cells this could lead to a very low level of PAK1 expression in the whole 
population of cells, potentially at undetectable levels. As passage number increased the 
PAK1 expressing cells could outcompete the PAK1 knockout cells causing a gradual 




The importance of PAK1 in breast cancer cell proliferation has previously been reported, 
notably in MDA-MB-231 cells (Zhan et al., 2017). Additionally, whilst culturing both the 
shRNA PAK1 knockdown cells and the CRISPR PAK1 knockdown cells no obvious 
differences in cell proliferation rate were noted compared to wild-type MDA-MB-231 cells. 
It is therefore improbable that a PAK1 knockdown cell population would proliferate at 
such an accelerated rate with regards to wild type cells and result in undetectable levels 
of PAK1 expression. 
When assessing both morphological and migratory phenotypes, it would be expected that 
a population of cells containing PAK1 knockout and PAK1 expressing cells would give rise 
to two different phenotypes. However, in CRISPR PAK1 knockdown cells, 1.22 and 2.10, 
only one phenotype is observed for both morphological and migratory analysis (Figure 3.8 
and 3.9). In addition to this comparisons of the shRNA PAK1 knockdown cells and CRISPR 
PAK1 knockdown cells exhibit similar phenotypes with regards to cell size (Figure 3.3 and 
3.8) and mean speed of cell migration (Figure 3.4 and 3.9). This would suggest the re-
expression of PAK1 detected in the CRISPR PAK1 knockdown cells, 1.22 and 2.10, is not as 
a result of a mixed cell population.  
Although a complete PAK1 knockout MDA-MB-231 cell line was not generated, two PAK1 
knockdown cell line using CRISPR-Cas9 technology with an average knockdown of 48% and 
57% respectively at passage eight were established. It is not surprising a depletion of PAK1 
alters the cells area and perimeter as PAK1 has previously been reported to play a role in 
the cytoskeletal changes in many different cell types in overexpression studies. In both 
fibroblasts and HeLa cells expression of constitutively active PAK1 causes loss of stress 
fibres and focal adhesions (Manser et al., 1997). In Swiss 3T3 cells microinjection of PAK1 
causes rapid formation of filopodia and membrane ruffles (Sells et al., 1997). It has also 
been demonstrated that PAK1 can induce cytoskeletal changes in breast cancer cells. 
Talukder et al., 2006 demonstrate than an increase in PAK1 activity, in in the MCF-7 breast 
cancer cell line, causes an increase in lamellipodia structures at the leading edge and a 
decrease in stress fibres and focal adhesions.  Similarly, in MCF-7 cells overexpression of 
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PAK1 causes cell ruffling on stimulation with prolactin (Hammer et al., 2013). However, 
the effect of PAK1 depletion in the morphology of MDA-MB-231 cells has not previously 
been reported.  
In this chapter it is demonstrated knockdown by both shRNA and CRISPR-Cas9 technology, 
and pharmacological inhibition of PAK1 causes a decrease in cell spread area. The average 
area of shRNA and CRISPR knockdown cells are comparable (Table 3.1), with small 
differences most likely accounted for by varying levels of PAK1 knockdown. The IPA-3 
treated cells showed a bigger cell spread area compared to both types of knockdown cells. 
This could indicate a role independent of PAK1 kinase activity, potentially as a scaffold 
protein. Although, as the IPA-3 treated cells have a significantly smaller area than the 
wildtype of DMSO controls (Figure 3.11) the majority of the decrease cell spread area 
phenotype which arises by manipulating PAK1 can probably be attributed to its kinase 
activity.  
Cellular studies highlighting PAK1’s ability to influence cell migration have been widely 
reported. Adam et al (1998) demonstrate a role for endogenous PAK1 in reorganising of 
the actin cytoskeleton, when stimulated with heregulin, to increase cell migration and 
invasion of MCF-7 cells. Additionally, in MCF-7, hyperactivation of PAK1 using a 
catalytically active mutant promotes cell migration of this non-invasive breast cancer cell 
line (Vadlamudi et al., 2000).  
Studies also support the findings in this chapter that a decrease in PAK1 activity causes a 
decrease in cell migration, specifically in MDA-MB-231 cells. Overexpression of a kinase- 
dead PAK1 mutant in MDA-MB-231 causes enhanced stress fibres and a reduction in 
invasiveness (Adam et al., 2000). Stimulation studies also highlight a role for PAK1 in MDA-
MB-231 cell migration. Yang et al (2011) demonstrate PAK1 activation on EGF stimulation 
which increased cell migration. They also find expression of a dominant negative PAK1 
mutant largely abolishes EGF-induced cell migration (Yang et al., 2011). Furthermore, 
lysophosphatidic acid stimulation also induces PAK1 activation and increases cell 
migration, whilst an inactive mutant of PAK1 inhibits cell migration (Du et al., 2010). In this 
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chapter the mean cell speed of the shRNA PAK1 knockdown, CRISPR PAK1 knockdown and 
IPA-3 treated cells indicate the role of PAK1 is dependent on PAK1 kinase activity and 
cannot be attributed to kinase independent functions (Table 3.2). This effect of IPA-3 on 
MDA-MB-231 cell migration has not previously been published and strongly indicated 
PAK1 kinase activity is important for cell migration.   
This chapter highlights the importance of PAK1 kinase activity in breast cancer cell 









































WT (IPA-3) 301 DMSO 303 IPA-3 203 
Table 3.1 Area values for shRNA, CRISPR and IPA- 3 morphology.
shRNA and CRISPR cell values are an average of three independent experiments, 30 cells per 
experiment.  IPA-3 values are an average of three time-points (2, 4 and 6 hours) assessed for 
independent experiments, 30 cells per experiment.  
 
Table 3.2 Mean cell speed values for shRNA, CRISPR and IPA- 3 morphology. Values are an 
average of three independent experiments, 20 cells per experiment 
 
  










Mean cell speed 
(µm/min) 
WT (shRNA) 1.58 Control 1.48 Sh1 0.77 
Sh2 0.65 








WT (IPA-3) 1.50 DMSO 1.47 IPA-3 0.84 
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3.4 Future work  
This chapter describes the phenotypes that arose from depletion of PAK1 in MDA-MB-231 
cells. PAK1 depletion causes altered morphology and motility of these breast cancer cells. 
Confirming these findings in other breast cancer cell lines would further highlight the 
importance that PAK1 plays in breast cancer cell migration. Comparing PAK1 depletion 
phenotypes in TNBC cell lines to hormone receptor and HER2 positive breast cancers 
would also assess the requirement for PAK1 in highly invasive breast cancers. 
Furthermore, it would also be noteworthy to see if these PAK1 kinase dependent functions 
were conserved to other cancer cell lines, for the example if the same phenotypes were 
observed in PaTu-8988T cells which also express PAK1 at high levels.  
As a complete PAK1 knockout cell line would be beneficial to studying the role of PAK1 in 
morphology and migration, sequencing the CRISPR PAK1 knockdown cells to confirm if a 
successful CRISPR event had altered any of the PAK1 copies in these cell populations would 
aid the explanation of PAK1 re-expression. If the CRISPR construct had successfully altered 
one or multiple of the PAK1 copies, it would be appropriate to subject the CRISPR PAK1 
knockdown cell populations to CRISPR-Cas9 technology again, to generate an MDA-MB-
231 cell line with no PAK1 expression.  A complete absence of PAK1 expression would need 
to be confirmed by assessing protein and mRNA levels.   
A complete knockout PAK1 cell line would provide a useful tool to further study PAK1 
activity and cell migration as constitutively active or kinase dead mutants could be 
knocked in using CRISPR-Cas9 technology. The role of PAK1 kinase activity could then be 
assessed when expression is at endogenous levels rather than an overexpression or 
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Chapter 4 Assess the requirement of PAK1 activity in in 
vitro invasion and in vivo cell migration 
4.1 Introduction  
Chapter 3 has highlighted a key role for PAK1 kinase activity in breast cancer cell 2D 
migration and morphology, which is supported in the literature. Whilst morphological 
analysis and 2D migration studies are useful for elucidating the importance of proteins in 
migration they are limited regarding their physiological relevance to cell migration and 
metastasis in patients. 3D in vitro systems, also termed spheroid assays, offer a bridge 
between 2D and in vivo studies.  
Spheroid assays offer several advantages as they permit the study of cell migration and 
invasion in 3D, which allows further investigation of proteins thought to be important in 
cancer cell migration. Spheroid assays also allow drug screening in a more physiological 
environment in comparison to 2D migration studies (Rodrigues et al., 2018). It is therefore 
no surprise that 3D in vitro systems are becoming a popular method to study cancer cell 
invasion however they still offer less physiological relevance compared to in vivo cell 
assays which utilise model organisms such as mice and zebrafish to study cancer cell 
migration.  
Zebrafish (Danio rerio) offer many advantages as an in vivo model and therefore they are 
becoming increasingly popular in many fields, including oncology research and the study 
of metastasis (Liu and Leach, 2011).  Zebrafish embryos are optically translucent and are 
ideally suited to high resolution live imaging (Falenta et al., 2013). Zebrafish breed in large 
numbers so a single mating pair can produce hundreds of embryos in one spawn and 
develop rapidly ex-utero (Rubinstein, 2003).  Comprising many advantages as a model for 
cancer metastasis, zebrafish offer a viable alternative to mouse studies to image cancer 
cell dissemination in vivo (Stoletov and Klemke, 2008, Amatruda et al., 2002).  
Zebrafish embryos allow xenotransplantation assays using fluorescently labelled cancer 
cells at two days post fertilisation (dpf) when these cells are injected into the embryo, 
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usually into the yolk sac, and dissemination of the cancer cells to distant sites is detected 
using fluorescent microscopy. This assay allows the invasion, migration and 
micrometastasis formation of the injected cancer cells to be observed and studied. The 
zebrafish xenograft assay allows quick evaluation of metastasis formation, with 
dissemination and colonisation of cancer cells at distant sites occurring within 5 days of 
embryo injection. In comparison, in vivo mouse studies can take weeks until metastases 
can be detected. For this reason using the zebrafish xenograft model is becoming an 
increasingly popular method to study cancer cell invasion and metastasis with studies 
conducted in a range of cancer types such as melanoma (Lee et al., 2005), leukaemia 
(Pruvot et al., 2011), breast (Stoletov et al., 2010) and pancreatic cancer (Marques et al., 
2009).   
Despite the development of both these assays to study breast cancer cell invasion and 
migration, very little is reported about PAK1 in such assays, and the role of PAK1 kinase 
activity in assays which offer more physiological relevance is mostly unknown. This 
chapter therefore aims to examine if PAK1 plays a role in 3D invasion and in vivo cell 
migration by utilising spheroid and zebrafish xenograft assays, and if so whether this is a 









4.2.1 PAK1 kinase activity plays a role in 3D cell invasion 
Previously PAK1 knockdown cells were generated using shRNA technology (Figure 3.2) and 
were shown to have altered morphology (Figure 3.3) and slower migration (Figure 3.4) 
compared to wildtype and control cells. Initially, 3D spheroid invasion was investigated.  
Wildtype, control and PAK1 knockdown cells were subjected to a 3D spheroid invasion 
assay. Cell spheroids are formed, embedded in a collagen matrix and allowed to invade 
for 24 hours. The number of cells invading into the collagen is calculated per quadrant. 
Both populations of PAK1 knockdown cells (sh1 and sh2) showed a decrease number of 
cells invading per quadrant compared to wildtype and control cells (Figure 4.1) 
MDA-MB-231 cells depleted for PAK1 using CRISPR-cas9 technology were also generated 
(Figure 3.8) and displayed an altered morphology (Figure 3.9) and decrease migration 
(Figure 3.10) compared to wildtype controls. These cells were therefore utilised to 
investigate the role of PAK1 in cell invasion. All experiments using these cells occurred 
before passage number eight; therefore, ensuring significant PAK1 knockdown compared 
to wildtype cells (Figure 3.8). Similarly, to the shRNA PAK1 knockdown cells, the CRISPR 
PAK1 knockdown cells also show a decrease in the number of cells invading per quadrant 
compared to wildtype controls (Figure 4.2). 
Previous experiments demonstrate that PAK1 kinase activity is important in cell 
morphology and migration as when IPA-3, a PAK1 kinase inhibitor, is employed cells have 
altered morphology (Figure 3.11) and impaired migration (Figure 3.12) compared to 
wildtype and DMSO control cells. The IPA-3 treated cells also show a reduction in the 
number of invading cells compared to wildtype or DMSO treated control cells (Figure 4.3) 





















Figure 4.1 shRNA PAK1 knockdown leads to a decrease in cell invasion. Wildtype, control and PAK1 
knockdown cells (sh1 and sh2) were seeded into non-adherent U-bottom 96 well plate and allowed 
to form spheroids. (A) Representative images of wildtype, control and PAK1 knockdown cells at 0h 
and 24h in a collagen matrix. Scale bar represents 300µm. (B) Graphical representation of the 
number of cells invading into the surrounding collagen per quadrant. Error bars represent SEM for 
three independent experiments, three spheroids analysed per condition, per experiment. Statistical 
























Figure 4.2 CRISPR PAK1 knockdown leads to a decrease in cell invasion. Wildtype and CRISPR PAK1 
knockdown cells (1.22 and 2.10) were seeded into non-adherent U-bottom 96 well plate and 
allowed to form spheroids. (A) Representative images of wildtype and PAK1 knockdown cells at 0h 
and 24h in a collagen matrix. Scale bar represents 300µm. (B) Graphical representation of the 
number of cells invading into the surrounding collagen per quadrant. Error bars represent SEM for 
three independent experiments, three spheroids analysed per condition, per experiment. Statistical 
























Figure 4.3 IPA-3 treatment leads to a decrease in cell invasion. Wildtype, DMSO treated and IPA-3 
treated MDA-MB-231 cells were seeded into non-adherent U-bottom 96 well plate and allowed to 
form spheroids. (A) Representative images of wildtype, DMSO treated and IPA-3 treated cells at 0h 
and 24h in a collagen matrix. Scale bar represents 300µm.  (B) Graphical representation of the 
number of cells invading into the surrounding collagen per quadrant. Error bars represent SEM for 
three independent experiments, three spheroids analysed per condition, per experiment. Statistical 
analysis was carried out using t-tests (*** p<0.001). 
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4.2.2 Zebrafish xenograft assay to study cancer cell migration 
Having translated the 2D findings to 3D the next step was to investigate the requirement 
of PAK1 kinase activity in in vivo cell migration.  
To gain the required technical skills for the zebrafish xenograft assay initial experiments 
were performed using AsPC-1 cells, a pancreatic cell line known to perform optimally in 
this assay (Teng et al., 2013).  
AsPC-1 cells labelled with a fluorescent cell tracker dye were injected into the yolk sac of 
2dpf zebrafish embryos. Two hours post injection the embryos were screened for the 
presence of fluorescence in the yolk sac (Figure 4.4A) and 24 hours after injected the 
embryos were screened for the presence of fluorescent deposits in the tail outside of the 
vasculature, indicating dissemination of AsPC-1 cells from the yolk sac to the tail (Figure 

































Figure 4.4 AsPC-1 cells dissemination in a zebrafish xenograft assay. Fluorescently labelled AsPC-1 
cells were injected into 2dpf zebrafish embryos. (A) Representative image of an embryo with a 
positive fluorescent signal in the yolk sac two hours after injection. The asterisk indicates the site of 
injection. (B) Representative image of an embryo with positive dissemination marked by arrows, 24 
hours after injection. (C) Graphical representation of the percentage of embryos with dissemination. 
Error bars represent the SEM for three independent experiments, with a minimum of 12 embryos 




4.2.3 Development of fluorescent MDA-MB-231 cells for zebrafish 
xenograft assay 
Prior to MDA-MB-231 xenograft experiments it was necessary to generate fluorescently 
labelled cell lines, as the cell tracker dye previously used for AsPC-1 cell experiments does 
not label cells for an adequate amount of time to allow detection of MDA-MB-231 cells 
4dpi. Wildtype, shRNA control cells and sh2 PAK1 knockdown cells were virally infected 
with LifeAct-RFP which labels the actin cytoskeleton. Sh2 cells were selected over sh1 cells 
as they express a lower level of PAK1 (Figure 3.2). Unfortunately, as the CRISPR PAK1 
knockdown cells show an increase in PAK1 expression as the cells’ passage number 
increases (Figure 3.8), it would not be viable to generate these cells with LifeAct-RFP, as 
the PAK1 expression would no longer be significantly reduced after the viral infection 
protocol had been completed.  
















Figure 4.5 Successful generation of wildtype, control and PAK1 knockdown cells labelled with 
LifeAct-RFP.Representative images of wildtype, control and PAK1 knockdown cells, sh2, expressing 
LifeAct-RFP which labels the actin cytoskeleton, DAPI which stains the nucleus and GFP which here 




4.2.4 Optimisation of the zebrafish xenograft assay for MDA-MB-231 cells  
Once the fluorescent wildtype, control and PAK1 knockdown MDA-MB-231 cells were 
generated a protocol previously used in the Wells’ lab was employed to inject the cells 
into the yolk sac of the embryo, to establish a successful xenograft. Unfortunately, this 
protocol was not sufficient to xenograft the cells into the embryos and therefore needed 
to be optimised for the MDA-MB-231 cells. Three parameters of the experimental 
conditions were assessed on two different readouts, the percentage of embryos which 
died and the percentage of embryos with a successful xenograft, 24 hours after injection. 
All optimisation procedures were performed using wildtype MDA-MB-231 cells labelled 
with LifeAct-RFP (Figure 4.5).  
Firstly, the size of the needle was assessed as previously in the Wells’ lab two different 
sizes had been used depending on the cells being injected. Needles with the internal 
diameters of 0.58mm and 0.78mm were assessed. The 0.78mm needle was selected as it 
resulted in a higher percentage of embryos with a successful xenograft (Table 4.1).  
Secondly, the density of the cells injected was optimised. MDA-MB-231 cells were 
prepared at 1.6 x 10
4, 2.1 x 10
4 and 3.2 x 10
4 cells per µl. These densities were selected 
from previous protocols in the Wells’ lab and appropriate literature. The 2.1 x 10
4cells/µl 
density was selected as it resulted in a higher percentage of embryos with a successful 
xenograft (Table 4.2). 
 
Finally, the pulse duration of injection was optimised. Three pulse durations were 
assessed- 200, 400 and 600ms based on previous protocols used in the Wells’ lab. The 
600ms duration gave a highest percentage of embryos with a successful xenograft 
compared to the 400ms condition, however the high percentage of embryo death in this 
condition meant the small increase in percentage of embryos with a successful xenograft 
was deemed not beneficial (Table 4.3).  The 400ms duration was therefore selected as it 
resulted in a high percentage of embryos with successful xenografts and relatively low 
percentage of embryo death at 24 hours (Table 4.3). 
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For all further zebrafish xenograft experiments cells prepared at a density of .1 x 
10
4cells/µl were injected using a needle with a 0.78mm internal diameter with a pulse 
















Table 4.1 Zebrafish xenograft assay needle size optimisation.
 Values are averages of three independent experiments, 100 embryos injected per experiment, 
per condition.  
 Table 4.2 Zebrafish xenograft assay cell density optimisation. Values are averages of three 




Percentage of fish dead at 24 
hours (%) 
Percentage of fish with 









600  55 67 
 
Table 4.3 Zebrafish xenograft assay pulse duration of injection optimisation. Values are averages 
of three independent experiments, 100 embryos injected per experiment, per condition.   
 
Percentage of fish dead at 24 
hours (%) 
Percentage of fish with xenograft 












Percentage of fish dead at 24 
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4.2.5 PAK1 kinase activity plays a role in in vivo cell migration 
Once the zebrafish xenograft assay had been optimised for MDA-MB-231 cells the 
requirement for PAK1 in in vivo cell migration was assessed.  Wildtype, control and sh2 
cells were injected into 2dpf zebrafish embryos. 24 hours after injection the embryos were 
screened from the presence of fluorescence in the yolk sac (Figure 4.6A) and 4dpi the 
embryos were screened for the presence of fluorescent deposits in the tail, outside of the 
vasculature, indicating dissemination of MDA-MB-231 cells from the yolk sac to the tail 
(Figure 4.6B). The percentage of embryos with dissemination when injected with the sh2 
PAK1 knockdown cells was significantly decreased compared to embryos injected with 
both wildtype and control cells (Figure 4.6C). 
This demonstrates PAK1 is important in in vivo cell migration however it remained unclear 
if this is due to its kinase activity. To assess this wildtype cells were injected into 2dpf 
embryos and after 24 hours the embryos were screened for fluorescence in the yolk sac 
(Figure 4.7A), the embryo water was then supplemented with either DMSO or IPA-3, the 
inhibitor of PAK1 kinase activity. A 5µM concentration of IPA-3 was used based on 
previous publications (Jagadeeshan et al., 2017). A control of water that embryos are 
normally kept in was also present. 4dpi the embryos were screened for the presence of 
fluorescent deposits in the tail, outside of the vasculature, indicating dissemination of 
MDA-MB-231 cells from the yolk sac to the tail (Figure 4.7B). The percentage of embryos 
with dissemination when the embryo water was supplemented with IPA-3 was 
significantly reduced compared to the percentage of dissemination seen from embryos in 























Figure 4.6 PAK1 knockdown leads to a decrease in in vivo cell migration. LifeAct-RFP wildtype, 
control and PAK1 knockdown (sh2) cells were injected into 2dpf zebrafish embryos. (A) 
Representative image of an embryo with a positive fluorescent signal in the yolk sac 24 hours after 
injection. (B) Representative images of embryos injected with wildtype, control and sh2 cells 4dpi. 
Arrows indicate sites of dissemination. (C) Graphical representation of the percentage of embryos 
with dissemination. Error bars represent the SEM for three independent experiments, with a 
minimum of 15 embryos per experiment, per condition. Statistical analysis was carried out using t-
























Figure 4.7 IPA-3 pharmacological inhibition of PAK1 leads to a decrease in in vivo cell migration. 
Wildtype cells were injected into 2dpf zebrafish embryos. (A) Representative images of embryos 
with a positive fluorescent signal in the yolk sac 24 hours after injection. (B) Representative images 
of embryo maintained in routine water or water supplemented with DMSO or IPA-3 4dpi. Arrows 
indicate sites of dissemination. (C) Graphical representation of the percentage of embryos with 
dissemination. Error bars represent the SEM for three independent experiments, with a minimum 






This chapter aimed to assess the requirements of PAK1 in breast cancer cell 3D invasion 
and in vivo migration as little is known about PAK1 in this context. These two assays are 
useful tools to study cancer cell migration and invasion as they offer a greater physiological 
relevance than morphological and 2D migration studies.  
Firstly, a 3D spheroid invasion assay was employed to assess if PAK1 plays a role in breast 
cancer cell invasion in 3D. In this assay PAK1 knockdown via both shRNA and CRISPR-cas9 
technology showed a significant decrease in MDA-MB-231 cell invasion compared to 
wildtype and control cells (Figure 4.1 and 4.2). This highlighted the importance of PAK1 in 
3D cell invasion. To further explore kinase dependence IPA-3, the inhibitor of PAK1 kinase 
activity, was employed and demonstrated that this PAK1 function was dependent of its 
kinase activity, as IPA-3 treated MDA-MB-231 cells also show a significant decrease in cell 
invasion compared to wildtype and DMSO control cells (Figure 4.3). Although the role of 
PAK1 in 3D invasion is not extensively reported existing studies do support a role for PAK1 
in cell invasion, as demonstrated in this chapter.  
PAK1 also plays a role in 3D invasion of melanoma cells (Nicholas et al., 2016). Li et al 
(2008) report a critical role for PAK1 in Ras-transformed MCF10A cells when assessing 
invasion using a 3D reconstituted basal membrane overlay culture assay. Hammer et al 
(2013) demonstrate a role for PAK1 in 3D invasion of TMX2–28 cells, a highly invasive ER 
negative clone of MCF-7 breast cancer cells, believed to be due to PAK1s ability to aid 
expression and secretion of MMPs which can degrade the surrounding matrix.  
3D spheroid invasion assays demonstrated that PAK1 plays a role in breast cancer cell 3D 
invasion. To assess if PAK1 also plays a role in in vivo cell migration a zebrafish xenograft 
assay was employed.  
Zebrafish xenograft assays offer many advantages to study cancer cell invasion and 
metastasis. Whilst at first being challenging to learn, once the expertise of transplantation 
is learnt the assay it relatively simple and reproducible (Stoletov and Klemke, 2008). 
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Zebrafish spawn in large numbers allowing access to many embryos which develop ex-
utero (Rubinstein, 2003). These embryos are optically translucent meaning they are 
suitable for high resolution microscopy if desired and the zebrafish xenograft migration 
assay can be analysed by simple microscopy observations (Rodrigues et al., 2018). These 
factors ensure the assay is relatively cheap and simple way to study human cancer cell 
migration in vivo (Stoletov and Klemke, 2008).  In addition to this, the zebrafish embryos 
used for these assays have not yet developed an adaptive immune system but do however 
allow human cancer cell and innate immune system interactions (Rodrigues et al., 2018). 
Whilst 2D migration assays in the form of monolayer scratch and 2D random migration 
assays are much cheaper and offer better viability for the cancer cells being studied they 
are very substrate dependent and interactions between the cancer cells and extracellular 
environments are very limited and therefore less physiologically relevant that the 
zebrafish xenograft assay (Rodrigues et al., 2018). However, 2D migration assays are a very 
useful tool to identify proteins of interest involved in cell migration and invasion which 
may also play a key role in cancer cell metastasis and should therefore be studied in more 
detail.  
3D invasion assays offer a bridge between 2D migration and in vivo migration assays. In 
comparison to 2D migration assays they offer greater interactions between the cancer 
cells and ECM allowing the regulation of proliferation and differentiation of the cancer 
cells (Rodrigues et al., 2018). 3D assays are also relatively easy to perform, and 
identification of invading cancer cells by immunofluorescence or immunohistochemistry 
is simple (Rodrigues et al., 2018). They also offer a great platform for drug screening when 
investigation novel targets and pathways to combat cancer cell migration (Rodrigues et 
al., 2018). Whilst drug screening can be performed with zebrafish there are a lot more 
caveats involved when considering the drug effect on the zebrafish embryos itself and 
whether this could potentially be detrimental to the assay itself (Rubinstein, 2003).    
Drosophila also offer a valuable tool to study human cancers, particularly the initial stages 
of metastasis such as EMT, which is more challenging in zebrafish xenograft assays 
(Rodrigues et al., 2018). Whilst the genes and signalling pathways of drosophila have been 
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well studied and are highly conserved to humans, they lack mammalian systems and 
organs such as lungs, a liver and pancreas (Rodrigues et al., 2018). In this sense, zebrafish 
are more physiologically relevant in the study of cancer cell migration where the innate 
immune system is present, and angiogenesis can occur and be studied (Rodrigues et al., 
2018, Stoletov and Klemke, 2008).  
Mice are the one model organism routinely used which offer greater physiological 
relevance to humans than zebrafish (Rodrigues et al., 2018). They allow the formation of 
metastasis to relevant mammalian organs, e.g. the breast cancer cells metastasising to the 
lungs which naturally occurs in patients (Rodrigues et al., 2018, Dent et al., 2009). The 
study of metastasis formation in zebrafish xenograft assays is usually limited to the tail of 
the embryo and is therefore less physiologically relevant. However, mice need to be 
immunocompromised or immune-deficient meaning there is inadequate modelling of 
immune human responses (Rodrigues et al., 2018).  Although embryos in zebrafish 
xenograft assays have not developed and adaptive immune system they do allow the 
interaction of the human cancer cells and innate immune system (Rodrigues et al., 2018). 
Mice studies also take a lot longer and are more costly than other methods of studying 
cancer cell migration and invasion (Stoletov and Klemke, 2008, Amatruda et al., 2002). 
All methods offer advantages and limitations for studying cancer cell invasion and 
migration however all have a fundamental place in modern cell biology.  Depending on 
what exactly is being studied and the resources available a combination of these tools can 
be used to shed light onto proteins and pathways involved in cancer cell biology. The 
zebrafish method although initially challenging to learn can cover valuable middle ground 
between 2D/3D and mice assays when considering physiological relevance to human 
cancer metastasis in patients.  
 
In this chapter, the MDA-MB-231 cells did not initially xenograft successfully into the 
zebrafish using the existing injection protocol in the Wells’ lab. This is most probably 
because this protocol was optimised for a different cell type which may have different 
properties that influence their ability for a successful injection and xenograft. To overcome 
this obstacle three different experimental parameters were optimised. Firstly, the internal 
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diameter of the needle was optimised. The internal diameter size of 0.78mm was selected 
as it results in a greater number of embryos with successful xenograft 24 hours post 
injection (Table 4.1). This is most likely because the smaller diameter needle, 0,58mm, 
caused cell clumping within the tip of needle during injections, causing fewer cells to exit 
the needle and enter the yolk sac of the zebrafish.  The second parameter to be optimised 
was the density of the injected cells. The 2.1 x 10
4 cells/µl was selected for further 
injections as this cell density resulted in the highest percentage of successful xenografts 
at 24 hours post injection (Table 4.2). The lower density tested (1.6 x 10
4 cells/µl) was too 
low to ensure enough cells exited the needle and the higher density tested (3.2 x 10
4 
cells/µl) resulted in clumping of cells in the needle and therefore not enough entering the 
fish when injected. Finally, the last parameter tested was the pulse duration during 
injection. The pulse duration of 400ms was selected as it resulted in a high percentage of 
embryos with a successful xenograft in relation to the number of embryos dead at 24 
hours (Table 4.3). The 200ms pulse duration was too short to allow enough cells to exit 
the needle and the 600ms pulse duration most likely caused too much damage to the 
embryo which resulted in a higher percentage in embryo death compared to the other 
conditions (Table 4.3). MDA-MB-231 cells were successfully xenografted in a satisfactory 
number of zebrafish embryos when these experimental parameters were used.  
Here it is found wildtype MDA-MB-231 cells cause dissemination in ~21-22% of zebrafish 
embryos 4dpi. This is lower than numbers reported in the literature where dissemination 
was described to be >40% in control shRNA MDA-MB-231 cells (Li et al., 2016) and >75% 
in DMSO treated MDA-MB-231 cells (Xie et al., 2016). This is most likely due to significant 
difference in protocol. In previous studies there is a variation in site of injection, the 
zebrafish incubation temperature and the dissemination period.  For example, when 
injecting MDA-MB-231 cells, Xie et al (2016) injected into the yolk sac, maintained their 
embryos at 34°C and quantified the percentage of embryos with dissemination 2dpi 
whereas Li et al (2016) injected into the Duct of Cuvier, maintained their embryos at 33°C 
and quantified the percentage of embryos with dissemination just two hours post 
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injection. Injection into the Duct of Cuvier is a less robust way to study cell migration and 
dissemination than yolk sac injections, as the cells are injected directly into the embryos 
circulation. This accounts for why shorter time frames are used. The yolk sac is the only 
site of injection in the embryo which ensures migration can only be achieved through 
active cell motility (Veinotte et al., 2014), making injection into this site the most reliable 
way to assess a cell types ability to migrate. For the experiments reported in this chapter 
the cells are injected into the yolk sac, embryos are then maintained at 33°C and are 
analysed for percentage of embryos with dissemination 4dpi. An injection of 2dpf embryos 
into the yolk sac is the most commonly practiced variation and is adopted here. This is 
because it is an acellular environment which provides nutrients to the injected cells which 
allow for cell growth (Veinotte et al., 2014). 35oC has been suggested as the optimum 
temperature for the cancer cell survival and embryo development (Veinotte et al., 2014) 
however in the Wells’ lab a high rate of embryo cell death is observed at this temperature 
and therefore 33oC is used as it appears more suitable for this assay as there is less embryo 
death but MDA-MB-231 cells still survive and migrate.  
Interestingly, PAK1 has only once been previously published in any zebrafish xenograft 
migration studies however this was in melanoma cells (Nicholas et al., 2016). Here it is 
shown PAK1 plays a critical role for in vivo cell migration as injection of PAK1 knockdown 
cells causes a significant reduction in the percentage of embryos with dissemination 
compared to wildtype and control cells (Figure 4.6).  IPA-3 studies show this role of PAK1 
is dependent on its kinase domain as when this inhibitor is used to supplement the 
zebrafish water, a significant decrease in the percentage of embryos with dissemination 
compared to water not supplemented or supplemented with DMSO as a control is 
observed (Figure 4.7). It is important to note, the concentration of the IPA-3 inhibitor used 
to supplement the zebrafish water, 5µM, does not cause any damage to the embryos 
themselves (Jagadeeshan et al., 2017)  and therefore the results observed are due to the 
inhibitor of PAK1’s kinase activity and not due to any effect the drug could have on the 
zebrafish embryos development.  
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Taken together, this chapter highlights the importance of PAK kinase activity in 3D cell 
















4.4 Future work 
Confirming the requirement for PAK1 in 3D spheroid and zebrafish xenograft migration 
assays in other breast cancer cell line would further highlight the importance that PAK1 
plays in both 3D invasion and in vivo cell migration. For example, from chapter 3 and 
related literature it is apparent that the TNBC cell line BT-549 express PAK1, which has 
been shown to play a role in cell migration in this cell line (Zhan et al., 2017). It would be 
noteworthy to examine if PAK1 knockdown and pharmacological inhibition also caused a 
decrease in 3D cell invasion and in vivo cell migration. It would also be interesting to note 
if the zebrafish xenograft assay would perform more optimally if another cell type was 
used, for example the BT-549 cell line which has not been previously published in the 
zebrafish xenograft assay.  
Ideally, both the 3D invasion spheroid assay and zebrafish xenograft assay would be 
repeated using MDA-MB-231 cells which were complete knockout for PAK1 at the 
genomic level. The requirement of PAK1 and its kinase activity could then be assessed 
further by knocking in constitutively active or kinase dead mutants by utilising CRISPR-cas9 
technology, to a cell line with no PAK1 expression. The role of PAK1 kinase activity could 
then be assessed when expression is at endogenous levels rather than depletion or 
pharmacological inhibition of the protein. 
Confirming the findings here in other cancer cell lines in 3D cell invasion and in vivo cell 
migration could further support the concept that PAK1 could be an effective therapeutic 
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Chapter 5 Utilise an inducible PAK1 model system to 
monitor PAK1 specific cellular responses  
5.1 Introduction 
In chapter 3, PAK1 knockdown and pharmacological inhibition morphological studies 
implicated PAK1 in regulating cell spread area, a role dependent on PAK1 kinase activity 
(Figure 3.3, 3.9 and 3.11). Although many signalling pathways downstream of PAK1 in 
regards to cell migration are known, PAK1’s role in spreading is not well studied. Therefore 
little is known about the role of PAK1 in cell spreading and the downstream signalling 
effectors involved.  
Like in cell migration, cell spreading also requires rearrangement of the actin cytoskeleton. 
It is therefore not surprising that many of the key proteins involved in cell migration also 
have significant importance in cell spreading. For example, the Rho GTPases play essential 
roles in both cell spreading and migration (Lawson and Burridge, 2014). Rac1 is important 
for lamellipodia formation and cell spreading due it its ability to stimulate Arp2/3 via the 
WAVE complex (Miki et al., 1998, Machesky and Insall, 1998, Chen et al., 2017).  Rac1 also 
plays a role in focal complex formation as it is activated downstream of both integrin 
engagement and the FAK-Src complex, and is then recruited to membrane ruffles and 
adhesion sites via its binding to β-Pix (ten Klooster et al., 2006).  Interestingly, PAK1 has 
been shown to regulate the Rac1 and β-Pix interaction to controls cell spreading (ten 
Klooster et al., 2006). Like Rac1, PAK1 is activated downstream of integrin-dependent 
adhesion, and is implicated in focal adhesion regulation (Radu et al., 2014). Taken 
together, these studies indicate a role for PAK1 in cell spreading; however, this has not 
been widely researched especially in the context of breast cancer.  
Whilst studies have highlighted the importance of PAK1 and its kinase activity in cell 
spreading and migration, current methods employed to measure PAK1 activity have 
limitations. Phospho-PAK1 antibodies are employed to study PAK1 activity (Sells et al., 
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2000); however, this provides little insight into the role of PAK1 kinase activity in living 
cells, only highlights where active PAK1 is localised.  
Inducible systems offer an alternative approach to study kinase activity. Being able to 
activate a protein on demand allows the study of kinase activity in a temporal manner. 
Thus, kinase activity can be directly correlated with any observed cell behaviour changes. 
Therefore, to dissect a specific role in cell spreading, a PAK1 inducible system has been 
employed in this chapter.  
The inducible PAK1 construct is a single chain construct which combines iFKBP and FRB 
domains (together termed uniRapR) inserted into the 288-293 loop in the PAK1 kinase 
domain, an allosteric site which is not evolutionary conserved (Dagliyan et al., 2017). This 
site does not interact with any structural elements in the protein, including the regulatory 
domain and dimerisation interface (Dagliyan et al., 2017). This non-evolutionarily 
conserved loop allosterically coupled and moves in concert with the ATP-binding loop in 
PAK1’s kinase domain (Dagliyan et al., 2017). In the absence of rapamycin, the uniRapR 
domain renders the 288-293 loop and therefore the ATP binding-loop unstable  however 
on addition of rapamycin binding of the iFKBP and FRB domains occur thus stabilising both 








Figure 5.1 A schematic diagram of rapamycin induces PAK1-rap stability and activity. A uniRapR 
domain, which consists of an iFKBP and FRB domains, is inserted into the 288-293 loop of PAK1’s 
kinase domain. In the absence of rapamycin this causes instability of PAK1 due to the 
destabilisation of the ATP binding-loop in the kinase domain, indicated by a purple loop. On 
addition of rapamycin, indicated by the pink circle, the iFKBP and FRB domains of the uniRapR 
domain bind causing the kinase domain of PAK1 to become active, indicated by a yellow star, as 




Little is known about the specific role PAK1 plays in breast cancer cell dynamics and the 
downstream effectors involved in such events.  This chapter therefore aims to access the 
specific role of PAK1 in MDA-MB-231 morphological responses and identify putative 








5.2.1 UniRapR-PAK1 is stably expressed in MDA-MB-231 cells 
Wild-type MDA-MB-231 cells and MDA-MB-231 cells stably expressing an inducible PAK1 
construct (Figure 5.1) were received from Dr Klaus Hahn, University of North Carolina 
(Dagliyan et al., 2017). 
To confirm protein expression of the PAK1-rap construct in the MDA-MB-231 cells which 
are stably expressing the PAK1-rap construct (in this chapter termed S44 cells) and the 
absence of this expression in the wild-type cells that the S44 cells were derived from (in 
this chapter termed UNC-WT) cell lysates were probed for PAK1. Both the S44 and UNC-
WT cells show endogenous PAK1 expression at 68kDa, however only the S44 cells show 
expression of the PAK1-rap protein at 112kDa (Figure 5.2).  
For all subsequent experiments the UNC-WT cells are used as a control to eliminate any 
morphological or biochemical responses induced by rapamycin, given its inhibitory effects 






























Figure 5.2 Expression of PAK1-rap in S44 cells. Representative western blot from whole cell lysates 
were prepared from S44 and UNC-WT cells probed for PAK1. GAPDH was used as a loading control. 
Blot representative of three independent experiments. 
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5.2.2 Significant differences in cell morphology identified between MDA-
MB-231 wild-type populations 
During initial culturing for generation of lysates (Figure 5.2) it was observed that the UNC-
WT cells exhibited an increased spread area compared to wildtype MDA-MB-231 from 
King’s (K-WT) utilised in chapters 3 and 4. Subsequent cell spread area analysis revealed a 
significant difference between the two wildtype populations (Figure 5.3). Therefore, the 
UNC-WT cells were used as the wild-type control cells for the remainder of this chapter as 







































Figure 5.3 Morphology of K-WT and UNC-WT cells. (A) K-WT and UNC-WT cells were seeded onto 
coverslips, fixed and stained for DAPI and phalloidin. Cells were then subject to morphological 
analysis using ImageJ. The scale bar represents 10µm. (B and C) Graphical representation of cell 
area (B) and perimeter (C) for K-WT and UNC-WT cells. Error bars represent SEM for three 
independent experiments, 30 cells per experiment. Statistical analysis was carried out using t-tests 
(** p<0.01, *** p<0.001). 
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5.2.3 Phosphorylation levels of PAK1-rap increase on rapamycin stimulation  
To confirm the activation of the PAK1-rap construct on addition of rapamycin, S44 and 
UNC-WT were stimulated with rapamycin for five, 20 and 60 minutes. The cells were lysed 
and probed for pPAK1 threonine 423, as a marker of activation and kinase activity (Zenke 
et al., 1999). The samples were also probed for total PAK1 to ensure levels of total protein 
remained stable, and GAPDH as a loading control. An increase of pPAK1 thr423 of the 
PAK1-rap is observed at the five-minute time point for S44 cells however the 
phosphorylation level is beginning to decay within 20 minutes (Figure 5.4).  This increase 
is not observed in the UNC-WT cells as they do not express the PAK1-rap construct (Figure 
5.5). No increase in the phosphorylation of threonine 423 of endogenous PAK1 was 
































Figure 5.4 Phosphorylation levels of PAK1-rap at threonine 423 increase on stimulation of 
rapamycin in S44 cells. Whole cell lysates prepared from S44 cells stimulated with rapamycin for 
five, 20 and 60 minutes. (A) Representative western blot indicating the level of pPAK1 thr423 for 
the PAK1-rap protein and the level of total PAK1-rap protein. GAPDH was used as a loading control. 
(B) Densitometric analysis on ImageJ was used to compare the levels of pPAK1 thr423, normalised 
to the loading control and background noise. (C) Densitometric analysis on ImageJ was used to 
compare the levels of total PAK1, normalised to the loading control and background noise. Error 
bars represent SEM for three independent experiments. Statistical analysis was carried out using t-























Figure 5.5 No change in endogenous PAK1 threonine 423 phosphorylation levels on 
stimulation of rapamycin in S44 cells. Whole cell lysates prepared from S44 cells stimulated 
with rapamycin for five, 20 and 60 minutes. (A) Representative western blot indicating the 
level of PAK1 thr423 for the endogenous PAK1 and the level of total endogenous PAK1. 
GAPDH was used as a loading control. (B) Densitometric analysis on ImageJ was used to 
compare the levels of pPAK1 thr423, normalised to the loading control and background 
noise. (C) Densitometric analysis on ImageJ was used to compare the levels of total PAK1, 
























Figure 5.6 No change in endogenous PAK1 threonine 423 phosphorylation levels on 
stimulation of rapamycin in WT-UNC cells. Whole cell lysates prepared from WT-UNC cells 
stimulated with rapamycin for five, 20 and 60 minutes. (A) Representative western blot 
indicating the level of PAK1 thr423 for the endogenous PAK1 and the level of total 
endogenous PAK1. GAPDH was used as a loading control. (B) Densitometric analysis on 
ImageJ was used to compare the levels of pPAK1 thr423, normalised to the loading control 
and background noise. (C) Densitometric analysis on ImageJ was used to compare the levels 
of total PAK1, normalised to the loading control and background noise. Error bars represent 




5.2.4 Specific activation of PAK1 induces MDA-MB-231 cell spreading  
Having confirmed an increase in the phospho-thr423 levels of PAK1-rap, S44 cells were 
incubated with rapamycin for five, 20 and 60 minutes on coverslips, then fixed, stained 
and subjected to morphological analysis. 
On all the tested matrices (collagen, fibronectin and glass) activation of PAK1-rap induces 
a rapid cell spreading response; within five minutes. The increase in cell spread area is 
short lived with the stimulated cells returning to basal levels within 20 minutes (Figure 5.7 
and 5.8). No increase in cell area or perimeter was observed for the UNC-WT cells (Figure 


































Figure 5.7 Rapamycin activation of PAK1-rap induces S44 cell spreading. Representative images of 
S44 cells seeded on either glass, type I collagen or fibronectin and stimulated with rapamycin for 




























Figure 5.8 Statistical analysis of S44 cell spreading on rapamycin induced PAK1-rap activation. S44 
cells seeded on either glass, type I collagen or fibronectin and stimulated with rapamycin for five, 
20 or 60 minutes. The cells were fixed and stained with phalloidin and subject to morphological 
analysis using ImageJ. (A, C and E) Graphical representation of cell area on glass, type I collagen and 
fibronectin respectively. (B, D and F) Graphical representation of cell perimeter on glass, type I 
collagen and fibronectin respectively. Error bars represent SEM for three independent experiments, 





















Figure 5.9 No change in UNC-WT cell area or perimeter on rapamycin stimulation in UNC-WT cells. 
Representative images of UNC-WT cells seeded on either glass, type I collagen or fibronectin and 
stimulated with rapamycin for five, 20 or 60 minutes. The cells were fixed and stained with 


























Figure 5.10 Rapamycin stimulation of UNC-WT induced no significant changes to cell area or 
perimeter. UNC-WT cells seeded on either glass, type I collagen or fibronectin and stimulated with 
rapamycin for five, 20 or 60 minutes. The cells were fixed and stained with phalloidin and subject to 
morphological analysis using ImageJ. (A, C and E) Graphical representation of cell area on glass, type 
I collagen and fibronectin respectively. (B, D and F) Graphical representation of cell perimeter on 
glass, type I collagen and fibronectin respectively. Error bars represent SEM for three independent 
experiments, 30 cells per experiment. 
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5.2.5 Cytoskeletal phospho-array reveals changes in protein 
phosphorylation levels on PAK1 activation  
The identification of an acute cellular response (within five minutes) to PAK1 activation 
provided an opportunity to identify downstream targets most likely to drive this cell 
behaviour. Thus, a commercial cytoskeletal phospho-array which enables qualitative 
protein phosphorylation profiling analysis was employed.  
S44 cells stimulated with rapamycin for five minutes and S44 cells with no rapamycin 
stimulation (used as a baseline control) were lysed, biotinylated, incubated with the ELISA 
based antibody array and detected by dye conjugated streptavidin. The array slides were 
scanned (Figure 5.13) and changes in protein phosphorylation sites that occurred on PAK1 

































Figure 5.11 Cytoskeletal phospho-array slide images. Unstimulated and rapamycin stimulated S44 
cells were lysed and analysed using a cytoskeletal phospho-array. Each vertical line containing six 
dots is representative of a different antibody. The green and red boxes demonstrate proteins where 
the phosphorylation of a specific site has decreased or increased respectively on rapamycin induced 
PAK1 activation.  (A) Unstimulated S44 cell. (B) S44 cells stimulated with rapamycin for five minutes 




Protein Fold increase Fold decrease 
pCrkII Tyr221 - 2.2 
pVASP Ser238 - 1.7 
pCAMK2 Thr305 - 1.1 
pSrc Tyr418 - 1.1 
pEzrin Thr567 1.8 - 
pFAK Ser910 1.6 - 
pFAK Tyr925 1.6 - 
pPKC α/β II Thr638 1.4 - 
pC-Raf Ser296 1.3 - 
pMKK6 Ser207 1.3 - 
pCortactin Tyr421 1.2 - 
pLIMK1 Thr508 1.2 - 
pMyosin light chain 2 Ser19 1.2 - 
pERK3 Ser189 1.1 - 







5.2.6 Phosphorylation levels of LIMK1 threonine 508 and LIMK2 threonine 
505 increase on PAK1 activation 
An increase in cell area and perimeter on the rapamycin induced activation of PAK1 was 
observed (Figure 5.7 and 5.8) and an increase in the phosphorylation of LIMK1 threonine 
508 was observed on PAK1 activation in the cytoskeletal phospho-array (Table 5.1).  
LIMK is a known downstream target of PAK1 and has previously been implicated in PAK1 
dependent cytoskeletal changes (Edwards et al., 1999). Interestingly, it has previously 
been reported that expression of dominant negative LIMK inhibits Rac induced 
cytoskeletal reorganisations, membrane ruffling and lamellipodia formation (Edwards et 
al., 1999, Yang et al., 1998), indicating LIMK could play a role in cell spreading. It was 
therefore decided to examine whether the increase in LIMK phosphorylation on the array 
could be validated.  
S44 and UNC-WT cells were stimulated with rapamycin for five, 20 and 60 minutes. The 
cells were lysed and probed for phosphorylation levels of threonine 508 on LIMK1 and 
threonine 508 on LIMK2. Cells were also probed for total LIMK1 and total LIMK2 to ensure 
levels of total protein were not changing, and for GAPDH which was used as a loading 
control. An increase in pLIMK1/2 Thr508/Thr505 was observed at the five-minute time 
point but is beginning to decay within 20 minutes in the S44 cells (Figure 5.11). No increase 

























B C D 
Figure 5.12 Phosphorylation levels of LIMK1 threonine 508 and LIMK2 threonine 505 increase on 
PAK1 activation in S44 cells.Whole cell lysates prepared from S44 cells stimulated with rapamycin 
for five, 20 and 60 minutes. (A) Representative western blot indicating the level of pLIMK1/2 
thr508/thr505 and the level of total LIMK1 and total LIMK2. GAPDH was used as a loading control. 
(B) Densitometric analysis on ImageJ was used to compare the levels of pLIMK1/2 thr508/thr505, 
normalised to the loading control and background noise. (C and D) Densitometric analysis on ImageJ 
was used to compare the levels of total LMK1 and LIMK2 respectively, normalised to the loading 
control and background noise. Error bars represent SEM for three independent experiments. 
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Figure 5.13 No change in the phosphorylation levels of LIMK1 threonine 508 and LIMK2 threonine 
505 on PAK1 activation in UNC-WT cells. Whole cell lysates prepared from UNC-WT cells stimulated 
with rapamycin for five, 20 and 60 minutes. (A) Representative western blot indicating the level of 
pLIMK1/2 thr508/thr505 and the level of total LIMK1 and total LIMK2. GAPDH was used as a loading 
control. (B) Densitometric analysis on ImageJ was used to compare the levels of pLIMK1/2 
thr508/thr505, normalised to the loading control and background noise. (C and D) Densitometric 
analysis on ImageJ was used to compare the levels of total LMK1 and LIMK2 respectively, normalised 





5.2.7 Phosphorylation levels of CRKII tyrosine 221 decrease on PAK1 
activation  
To further validate the array, complementary to validation of an increase in phospho-
LIMK, the decrease in CRKII at tyrosine 221 was investigated (Table 5.1). S44 and UNC-WT 
cells were stimulated with rapamycin for five, 20 and 60 minutes, lysed and probed for 
phosphorylation levels of tyrosine 221 on CRKII using a phospho-specific antibody. A 
decrease in phospho-CRKII tyrosine 221 levels was observed at the five-minute time point 
in S44 cells which begins to recover at 20 minutes post treatment (Figure 5.14). No change 




































Figure 5.14 Phosphorylation levels of CRKII tyrosine 221 decrease on PAK1 activation in S44 cells. 
Whole cell lysates prepared from S44 cells stimulated with rapamycin for five, 20 and 60 minutes. 
(A) Representative western blot indicating the level of pCRKII tyr221. Vinculin was used as a loading 
control. (B) Densitometric analysis on ImageJ was used to compare the level of pCRKII tyr221, 
normalised to the loading control and background noise. Error bars represent SEM for three 






















Figure 5.15 No change in the phosphorylation levels of CRKII tyrosine 221 on PAK1 activation in 
UNC-WT cells. Whole cell lysates prepared from UNC-WT cells stimulated with rapamycin for five, 
20 and 60 minutes. (A) Representative western blot indicating the level of pCRKII tyr221. Vinculin 
was used as a loading control. (B) Densitometric analysis on ImageJ was used to compare the level 
of pCRKII tyr221, normalised to the loading control and background noise. Error bars represent SEM 
for three independent experiments. 
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5.2.8 Phosphorylation levels of FAK serine 910 increase on PAK1 activation 
LIMK and CRKII’s respective increase and decrease in phosphorylation successfully 
validated the cytoskeletal phospho-array. However, LIMK being a downstream target of 
PAK1 is not novel (Edwards et al., 1999), and the decrease in phosphorylation to a tyrosine 
residue of CRKII cannot be a direct target of PAK1, a threonine/serine kinase.  Other 
findings from the cytoskeletal phospho-array were therefore investigated.  
FAK has been implicated in cell spreading and migration (Owen et al., 1999) and two of its 
phosphorylation sites were shown to increase on PAK1 activation in the phospho-array 
(Table 5.1). Indeed the phosphorylation of FAK serine 910 was very intriguing, especially 
as this finding has only been previously reported once, which was not in breast cancer cells 
(Li et al., 2010).  
S44 and UNC-WT cells were stimulated with rapamycin for five, 20 and 60 minutes, lysed 
and probed for phosphorylation levels of serine 910 on FAK. GAPDH was also probed for 
as this was used as the loading control. In S44 cells an increase in the phosphorylation of 
FAK at serine 910 was observed at the five-minute time point which then begins to decay 
within 20 minutes (Figure 5.16). No change in the level the phosphorylation of FAK at 





























Figure 5.16 Phosphorylation levels of FAK serine 910 increase on PAK1 activation in S44 cells. 
Whole cell lysates prepared from S44 cells stimulated with rapamycin for five, 20 and 60 minutes. 
(A) Representative western blot indicating the level of FAK serine 910 and total FAK. GAPDH was 
used as a loading control. (B) Densitometric analysis on ImageJ was used to compare the level of 
pFAK ser910, normalised to the loading control and background noise. (C) Densitometric analysis on 
ImageJ was used to compare the level of total FAK, normalised to the loading control and 
background noise. Error bars represent SEM for three independent experiments. Statistical analysis 





















Figure 5.17 No change in the phosphorylation levels of FAK serine 910 on PAK1 activation in 
UNC-WT cells. Whole cell lysates prepared from UNC-WT cells stimulated with rapamycin for five, 
20 and 60 minutes. (A) Representative western blot indicating the level of FAK serine 910 and 
total FAK. GAPDH was used as a loading control. (B) Densitometric analysis on ImageJ was used 
to compare the level of pFAK ser910, normalised to the loading control and background noise. (C) 
Densitometric analysis on ImageJ was used to compare the level of total FAK, normalised to the 




5.2.9 Phosphorylation levels of ERK1 threonine 202 and ERK2 tyrosine 204 
remain constant on PAK1 activation  
The previous report identifying a PAK1 phosphorylation of FAK serine 910 established a 
dependence on ERK1/2 in colorectal cancer cells. Incubating PAK1 overexpressing cells 
with the ERK inhibitor U0126, caused a decrease in FAK serine 910 phosphorylation in a 
dose-dependent manner (Li et al., 2010). To test this hypothesis rapamycin treated S44 
cells were probed for ERK1/2 activation.  
S44 cells were therefore stimulated with rapamycin for five, 20 and 60 minutes. The cells 
were lysed and probed for phosphorylation levels of threonine 202 on ERK1 and tyrosine 
204 on ERK2. Vinculin was used as a loading control. No changes in pERK1/2 thr202/tyr204 

































Figure 5.18 No change in the phosphorylation levels of ERK1 threonine 202 and ERK2 tyrosine 204 
on PAK1 activation in S44 cells. Whole cell lysates prepared from S44 cells stimulated with 
rapamycin for five, 20 and 60 minutes. (A) A representative western blot indicating the 
phosphorylation level of ERK1 threonine 202/ERK2 tyrosine 204 and total ERK1/2. Vinculin was used 
as a loading control. (B) Densitometric analysis on ImageJ was used to compare the level of pERK1/2 
thr202/tyr204, normalised to the loading control and background noise. (C) Densitometric analysis 
on ImageJ was used to compare the level of total ERK1/2, normalised to the loading control and 
background noise. Error bars represent SEM for three independent experiments. 
158 
 
5.2.10 Phosphorylation levels of ERK3 serine 189 increase on PAK1 
activation 
Data here suggests the phosphorylation of FAK serine 910 upon PAK1 activation is not 
dependent on the activation of ERK1/2, therefore other kinases were considered. The 
serine 189 site on ERK3 has previously been identified as a substrate of PAK1 (De la Mota-
Peynado et al., 2011, Deleris et al., 2011), and was detected here in the cytoskeletal 
phospho-array (Table 5.1). ERK3 phosphorylation at serine 189 has previously been linked 
to changes in cell spread area in MDA-MB-231 cells (Al-Mahdi et al., 2015). To determine 
if the FAK ser910 phosphorylation was via ERK3 was phosphorylated following acute PAK1 
activation, S44 and UNC-WT cells were stimulated with rapamycin for five, 20 and 60 
minutes. The cells were lysed and probed for phosphorylation levels of serine 189 on ERK3. 
GAPDH was used as a loading control. An increase in pERK3 serine 189 levels were 
observed at the five-minute time point for S44 cells but this signal begins to decay within 
20 minutes (Figure 5.19). No change in pERK3 serine 189 levels was observed in UNC-WT 





























Figure 5.19 Phosphorylation levels of ERK3 serine 189 increase on PAK1 activation in S44 cells. 
Whole cell lysates prepared from S44 cells stimulated with rapamycin for five, 20 and 60 minutes. 
(A) Representative western blot indicating the level of ERK3 serine 189 and total ERK. GAPDH was 
used as a loading control. (B) Densitometric analysis on ImageJ was used to compare the level of 
pERK3 ser189, normalised to the loading control and background noise. (C) Densitometric analysis 
on ImageJ was used to compare the level of total ERK3, normalised to the loading control and 
background noise. Error bars represent SEM for three independent experiments. Statistical analysis 






















Figure 5.20 No change in the phosphorylation levels of ERK3 serine 189 on PAK1 activation in 
UNC-WT cells. Whole cell lysates prepared from UNC-WT cells stimulated with rapamycin for five, 
20 and 60 minutes. (A) A representative western blot indicating the phosphorylation level of ERK3 
serine 189 and total ERK3. GAPDH was used as a loading control. (B) Densitometric analysis on 
ImageJ was used to compare the level of pERK3 ser189, normalised to the loading control and 
background noise. (C) Densitometric analysis on ImageJ was used to compare the level of total ERK3, 




5.3 Discussion  
Whilst PAK1 has been implicated in cell spreading, due to its ability to regulate the actin 
cytoskeleton and focal adhesions (Radu et al., 2014), its role in breast cancer cell spreading 
has not been well established.  This chapter therefore investigates downstream signalling 
implicated in PAK1 activated cell spreading by utilising an inducible PAK1 system.  
First, the MDA-MB-231 wildtype and S44 cell received from Dr Klaus Hahn, University of 
North Carolina, were examined for their expression of the PAK1-rap construct. Successful 
expression of the PAK1-rap construct was identified in the S44 cells but not the wildtype 
MDA-MB-231 cells (Figure 5.2). This ensures appropriate expression of the PAK1-rap 
construct enabling further experiments to be performed using these cells.  
An increase in phosphorylation at threonine 423 on the PAK1-rap construct is observed 
when rapamycin is added to the S44 cells for five minutes, this signal decreases within 20 
minutes (Figure 5.4). The increase in PAK1 phosphorylation indicates the PAK1 kinase 
domain is active, confirming the addition of rapamycin causes the kinase domain of PAK1 
to stabilise and activate, therefore showing the PAK1-rap construct is functioning 
correctly. No increase in the levels of threonine 423 on endogenous PAK1 were observed 
in S44 cells or wildtype cells (Figure 5.5 and 5.6), ensuring the rapamycin was specifically 
activating the PAK1-rap only.  
Initially morphological experiments following addition of rapamycin were performed using 
wildtype cells from the Well’s lab (K-WT cells), wildtype cells from the Hahn lab (UNC-WT 
cells) and the S44 cells which are the UNC-WT cells engineered to express the PAK1-rap 
construct. A significant difference in cell area and perimeter was observed between K-WT 
cells and UNC-WT cells (Figure 5.3). This is most likely due to the heterogeneity of MDA-
MB-231 cells population. If these cells have been cultured using different approaches or 
reagents, over time selection of cells with specific properties may be favoured resulting in 




The PAK1 inducible system allowed a direct correlation between spread area and 
biochemistry and therefore morphological changes associated with this increase in PAK1 
activity were investigated. An increase in cell spread area is observed in the S44 cells at 
the five-minute time point on glass, collagen type I and fibronectin (Figure 5.7 and 5.8). 
This is compelling evidence for a direct role of PAK1’s role in regulating cell morphology 
and supports the findings of knockdown and pharmacological inhibition of PAK1 on cell 
morphology in chapter 3. 
Garcia Arguinzonis et al. (2002) highlight a role for PAK1 kinase activity in cell spreading of 
mouse cardiac fibroblasts. VASP negative cells have a significant increase in cell spread 
area, which is linked to elevated PAK1 activation (Garcia Arguinzonis et al., 2002). 
However, some studies report that PAK1 inhibits cell spreading. Constitutively active PAK1 
expression causes inhibition of cell spreading in baby hamster kidney-21 and HeLa cells 
due to its ability to regulate myosin light chain kinase phosphorylation of the regulatory 
myosin light chain (Sanders et al., 1999). This study conflicts with data presented in this 
chapter, however this could be due to the nature of the experiment performed. In this 
chapter, based on the phosphorylation of PAK1 at threonine 423, there appears to be only 
an acute temporal activation of PAK1 compared to a continuous overexpression of 
constitutively active PAK1 in the Sanders et al studies. This is likely to be a contributing 
factor to the opposing results observed from these studies.  
Adam et al. (2000) demonstrate that a lack of PAK1 kinase activity causes cell spreading. 
An overexpression of a kinase dead PAK1 mutant causes enhanced cell spreading in the 
MDA-MB-435 breast cancer cell line and conditional expression of a kinase dead PAK1 
mutant causes cell spreading and a decrease in cell invasiveness in MDA-MB-231 cells 
(Adam et al., 2000). This study appears to conflict with data reported in this chapter 
however this is potentially due to different interpretations of cell spreading. In this 
chapter, the cell spreading observed is not persistent as an increase in cell spread area is 
only observed at the five-minute time point and has returned to basal levels within 20 
minutes (Figure 5.7 and 5.8). As the cell spread area phenotype couples with the 
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activation of the kinase activity of PAK1 (Figure 5.4), and chapters 3 and 4 highlight a role 
in PAK1 kinase activity in breast cancer cell migration and invasion, the transient cell 
spreading observed in these experiments may be more accurately attributed to cell 
spreading during cell migration as opposed to a persistent cell spreading reported by 
Adam et al. (2000).  
It is unclear why the signal and morphological phenotypes decrease from 20 minutes. 
Although possible, it is unlikely the rapamycin is dissociating from the UniRapR domain as 
they bind with a very high affinity. It is more possible that once the PAK1-rap is activated 
it is shuttled elsewhere in the cell where it is no longer in close enough proximity to 
phosphorylate its downstream effectors. Alternatively, a phosphatase removes the 
phosphate group on the threonine 423 causing a decrease in the PAK1-rap kinase activity.  
Both scenarios would explain the decrease in phosphorylation signals of the downstream 
effectors studied (LIMK1/2, CRKII, FAK and ERK3) and the decrease in the cell spread area, 
at the 20 and 60-minute time points compared to the five-minute time point. It is 
important to note the tight correlation between the cells’ morphological response and the 
associated downstream signalling.   
An increase in pLIMK1/2 Thr508/Thr505 was observed at the five-minute time point but 
starts to decay within 20 minutes in the S44 cells (Figure 5.12). No increase was observed 
in the UNC-WT cells (Figure 5.13). The increase in LIMK phosphorylation levels mirrors the 
increase in PAK1 kinase activity which heavily supports data that illustrates LIMK as a 
downstream target of PAK1 (Edwards et al., 1999). Prunier et al. (2016) highlight the 
importance of LIMK in breast cancer cell invasion and cell morphology using the LIMK 
inhibitor, Pyr1.  Pry1 treated cells have a higher percentage of rounded cells compared to 
wildtype and control MDA-MB-231 cells (Prunier et al., 2016). This indicates a role for LIMK 
in cell morphology, as reported in this chapter. Li et al. (2013) demonstrate a role for LIMK 
in breast cancer cell invasion in vitro, as expression of a dominant negative mutant, RNA 
interference and pharmacological inhibition of LIMK all caused a decrease in breast cancer 
cell invasion. Interestingly, it has also been reported that expression of LIMK1 in MDA-MB-
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435 breast cancer cell line increased cell invasiveness in vitro and increase metastasis to 
the liver and lungs in vivo (Bagheri-Yarmand et al., 2006). Taken together it is clear LIMK 
plays a role in breast cancer cell morphology, migration and invasion which support the 
idea that the transient cell spreading on PAK1 activation observed in this chapter is 
potentially due to an increase in cell dynamics associated with cell migration.  
A decrease in CRKII phosphorylation at tyrosine 221 levels after five minutes of rapamycin 
induced PAK1-rap activation was observed (Table 5.1 and Figure 5.14). Many studies 
demonstrate a role for CRKII in cell migration and invasion in multiple cancer types 
(Rodrigues et al., 2005) which has been linked to PAK1 kinase activity (Rettig et al., 2012). 
Rettig et al. (2012) report PAK1 can phosphorylate CRKII at the serine 41 site which causes 
an increase in the cell motility and invasiveness of non-small cell lung carcinomas, due to 
the downstream down regulation of p120-catenin. This however is not a phosphorylation 
site present in the cytoskeletal phospho-array. Tyrosine 221 phosphorylation is shown to 
decrease on PAK1 activation, as PAK1 is a serine/threonine kinase this is not likely due to 
a direct interaction with PAK1. Phosphorylation of CRKII at tyrosine 221 has been reported 
to enhance CRKII interactions with SH3 domain proteins such as AbI (Anafi et al., 1996). 
Other studies suggest that phosphorylation of tyrosine 221 causes a decrease in cell 
migration (Takino et al., 2003) which is surprising as the findings in this chapter suggest 
PAK1 kinase activity, which is widely associated with an increase in cell migration, causes 
a decrease in the phosphorylation of tyrosine 221 on CRKII. The difference in cell type and 
expression levels PAK1 may explain the discrepancies observed between the findings in 
this chapter and Takino et al. (2003) as the experiments published in this paper were 
performed on non-cancerous human embryonic kidney or fibrosarcoma cell line where 
PAK1 has not been overexpressed.  
A CRKII Y221F mutant, which cannot be phosphorylated at tyrosine 221, fails to induce 
membrane ruffling and cell motility, which is most likely caused by the inability of CRKII to 
activate Rac signalling (Abassi and Vuori, 2002). This study conflicts with results displayed 
in this chapter, a decrease in CRKII tyrosine 221 phosphorylation caused by PAK1 kinase 
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activity does not support the role for PAK1 in cell spreading and migration. However, these 
experiments were conducted in COS-7 cells, a fibroblast like cell line derived from monkey 
kidney tissue, which were not overexpressing PAK1 and this could account for the different 
results obtained in this chapter.  
It remains unclear why an increase in PAK1 kinase activity would cause a decrease in CRKII 
221 tyrosine levels as this has not been previously reported in the literature. One 
hypothesis could be that this occurs as a feedback mechanism of PAK1 activation. When 
PAK1 is activated it could increase the activity of a phosphatase for the CRKII tyrosine site, 
this would then result in a decrease in cell ruffling and migration as described by both 
Takino et al. (2003) and Abassi and Vuori (2002). This hypothesis is supported by the 
increase in CRKII tyrosine 221 levels and decrease in cell spread area from the five-minute 
time point and 20 and 60-minute time points (Figure 5.14). An alternative hypothesis 
relates to other functions of the PAK1 kinase domain. On activation of PAK1-rap, it is 
possible multiple signalling pathways downstream are activated. The decrease in CRKII 
phosphorylation may be cause by PAK1 kinase activity but is not directly linked to the cell 
spreading phenotype.  
Further validation of the cytoskeletal phospho-array came from investigating the increase 
in FAK serine 910 levels observed on PAK1 activation (Table 5.1 and Figure 5.16). The FAK 
gene is amplified and overexpressed in breast cancers and expression often correlates 
with poor prognosis and incidence of metastatic disease (Luo and Guan, 2010), it is 
therefore not surprising the phospho-array and western blotting experiments indicate it 
in having a role in breast cancer cell spreading in this chapter. FAK has been implicated in 
cell spreading and migration in numerous studies (Luo and Guan, 2010).  
The effect of serine 910 phosphorylation on FAK is not well studied compared to other 
phosphorylation sites on the protein. However, a few studies have implicated 
phosphorylation of serine 910 to cell spreading and migration. Phosphorylation at the 
serine 910 site has been shown to play a role in regulating cell spreading and sarcomere 
reorganisation in cardiac myocytes (Chu et al., 2011). It has also been reported 
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phosphorylation at serine 910 recruits its downstream effectors PIN1 and PTP-PEST which 
colocalise with FAK to the lamellipodia of migration cells (Zheng et al., 2009). These 
effectors also cause dephosphorylation of FAK at tyrosine 397, via a pathway involving 
PAK1, and this causes an increase in cell migration and invasion (Zheng et al., 2009). This 
demonstrates a potential mechanism for how an increase in FAK serine 910 
phosphorylation could be linked to an increase in cell spreading and migration.  
An increase in FAK serine 910 phosphorylation has also linked to increased cell motility in 
colorectal cancer cell lines (Li et al., 2010). Interestingly signalling of Rac1, an upstream 
regulator of PAK1 kinase activity, increases serine 910 phosphorylation which plays a role 
in focal adhesion regulation during cell spreading (Flinder et al., 2011).  However, very 
little is known about the mechanistic or structural consequences of FAK phosphorylation 
at serine 910 causes to the FAK protein. The serine 910 residue sits in the N-terminal focal 
adhesion targeting (FAT) sequence which is responsible for the proteins localisation to 
focal adhesions (Kadare et al., 2015). Kadare et al. (2015) suggest that phosphorylation at 
this site is associated with FAT opening that is linked to focal adhesion turnover which can 
influence cell migration. These studies support the idea that an increase in serine 910 on 
FAK, seen on increased PAK1 kinase activity in this chapter, promotes cell spreading 
associated with cell migration.  
Previous reports of the relationship between PAK1 and FAK serine 910 suggested it was 
via ERK1/2 (Li et al., 2010, Hunger-Glaser et al., 2004, Jiang et al., 2007) although none of 
these reporting studies are performed using breast cancer cells. No increase in ERK1/2 
activity is observed on the rapamycin induced activation of PAK1 (Figure 5.18), therefore 
the FAK serine 910 phosphorylation on PAK1 activation is not likely due to ERK1/2 activity 
as previously demonstrated in the literature. Interestingly, Villa-Moruzzi (2007) reports 
ERK1/2 does not phosphorylate FAK at the serine 910 site in MDA-MB-231 cells, thus 
supporting the hypothesis that the kinase responsible for FAK serine 910 phosphorylation 
differs between cell lines. In this study, ERK5 is implicated as the kinase responsible for 
FAK serine 910 phosphorylation (Villa-Moruzzi, 2007).  
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As phosphorylation of FAK serine 910 does not appear to be dependent on ERK1/2 activity, 
other proteins that could mediate this phosphorylation event were studied. ERK3 serine 
189 phosphorylation increased with PAK1 activity in the cytoskeletal phospho-array and 
western blots (Table 5.1 and Figure 5.19) although interestingly, there have been no 
previous publication linking ERK3 and FAK. However, it could be hypothesised that PAK1 
induces phosphorylation of FAK at serine 910 via ERK3, this hasn’t previously been 
reported although is plausible. ERK3 is a known downstream effector of PAK1 (De la Mota-
Peynado et al., 2011, Deleris et al., 2011) and it is able to phosphorylate serine residues 
(Boulton et al., 1991).  
ERK3 is a member of the atypical MAP kinase family however its physiological role is not 
well known (Al-Mahdi et al., 2015). Whilst no mutations are reported in the gene coding 
for ERK3 in breast cancer (Kostenko et al., 2012) it is reported to be overexpressed in the 
transcriptome of breast cancers associated with metastasis (Evtimova et al., 2001). It is 
not surprising ERK3 was identified as a downstream effector of PAK1 in the cytoskeletal 
phospho-array as it has previously been implicated in cancer cell migration and 
cytoskeletal regulation. ERK3 been shown to promote head and neck cancer cell migration 
(Elkhadragy et al., 2017) and the invasiveness of lung cancer in vitro and in vivo (Long et 
al., 2012). However, the role ERK3 in breast cancer has not been widely studied. In MDA-
MB-231 cells, overexpression of ERK3 causes an increase in cell migration (Al-Mahdi et al., 
2015). This study also implicated ERK3 expression with a reduction in cell spread area, 
however this is in a longitudinal study, not comparable to the assays performed in this 
chapter (Al-Mahdi et al., 2015).  Although not the main focus of the paper, Al-Mahdi et al. 
(2015) did report a decrease in cell spread area of ERK3 knockdown cells at an early time 
point when MDA-MB-231 cells are seeded onto collagen coated coverslips a much more 
closely related observation to studies performed here. This implicates ERK3 in cell 
spreading which is also observed in this chapter, due to the tight correlation of MDA-MB-
231 cell spreading (Figure 5.7 and 5.8) and an increase in ERK3 activity (Figure 5.19).  
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Thus, in this study, findings demonstrated PAK1 kinase activity induces cells spreading and 
have highlighted the immediate downstream effectors that could play a role in breast 

















5.4 Future work 
5.4.1 Further exploration of FAK and ERK3 
Having identified PAK1 and its downstream effectors, ERK3 and FAK, have a potential role 
in spreading in this inducible system, it would be important to validate this in wildtype 
MDA-MB-231 cells. To do so nascent cell spreading would need to be stimulated. This 
could be done using a drop assay where cells are detached from a flask with cell 
dissociation buffer and dropped onto a new plate. After a specified amount of time the 
dropped cells could be lysed, and westerns would indicate if the PAK1 threonine 423, the 
FAK serine 910 and the ERK3 serine 189 levels had increased. Wildtype cells which were 
lysed when pelleted before being dropped onto a different plate would be used as a 
control in this experiment. This would give further confirmation that these proteins and 
phosphorylation sites are important in cell spreading.  
Another way to confirm the importance of ERK3 and FAK in this spreading cascade would 
be to knockdown each protein individually in S44 cells, repeat the rapamycin induced 
PAK1 activation spreading experiment and observe if there were any significant 
differences in cell spread area compared to wildtype and control cells. This would also 
help confirm if PAK1 phosphorylated FAK serine 910 directly or if this is caused indirectly 
via ERK3 serine 189 activation. Interaction studies between the three proteins could also 
aid understanding of this signalling cascade.   
Creating stable MDA-MB-231 ERK3 and FAK knockdown cells and subjecting these to 
morphological, 2D migration, 3D invasion and in vivo zebrafish xenograft assay, as 
performed in chapters 3 and 4, would also confirm the importance of these proteins in cell 





5.4.2 Further exploration into the reduction in cell spreading and 
downstream signalling 
Research into why the PAK1 induced spreading and downstream signalling only occurs 
between 0 and five minutes would be useful. There are multiple theories to explain why 
this occurs. For example, the PAK1-rap construct could be shuttled by another protein 
inside the cell, away from its downstream effectors. Continuous phosphorylation of PAK1 
to its downstream effectors would therefore not be possible and signalling would stop, 
causing the decrease in cell spread area and phosphorylation of downstream proteins. As 
the PAK1-rap construct is mCherry tagged this could be used to determine the localisation 
of the construct at different time points when the cells are stimulated with rapamycin 
using high resolution confocal microscopy.  
Alternatively, screening for a phosphatase which removes the phosphate group from the 
threonine 423 site of PAK1 could also explain why the spreading phenotype and 
downstream signalling decays. This could provide novel understanding of PAK1 regulation 
in MDA-MB-231 cells. A phosphatase which causes a decrease in PAK1 signalling would 
also be a potential therapeutic target; however, where specific activation of this enzyme 
rather than inhibition could help reduce breast cancer cell migration, and therefore the 




























Chapter 6 Concluding remarks 
Triple negative breast cancer is heavily associated with poor prognosis, short progression 
free survival and low overall survival (Costa and Gradishar, 2017). This disease is often 
lethal due to its highly aggressive and metastatic behaviour (Dent et al., 2007). Treatment 
of TNBC relies on standard chemotherapy regimens and cannot benefit from targeted 
therapies used for ER and HER2 positive tumours which have significantly improved clinical 
outcomes (Reis-Filho and Tutt, 2008). There is a distinct lack of therapeutic targets for 
TNBC (Hudis and Gianni, 2011). This study therefore focused on the role that PAK1 plays 
in triple negative breast cancer cell spreading and migration and investigated whether it 
could be a potential therapeutic target to inhibit metastatic spread. Notably a key question 
posed was how important the kinase activity of PAK1 is in these cellular processes as this 
would lend PAK1 to pharmacological inhibition.  
First, PAK1 expression was noted in pancreatic, prostate and TNBC cell lines (Figure 3.1) 
indicating a role for the protein in cancer progression as previously published (King et al., 
2014).  This also allowed selection of the TNBC cell line with the highest PAK1 expression, 
MDA-MB-231. Establishing PAK1 knock down MDA-MB-231 cell lines via shRNA and 
CRISPR-Cas9 technologies allowed phenotypes resulting from PAK1 depletion to be 
studied. Both methods of PAK1 knockdown demonstrated an importance for PAK1 in 
MDA-MB-231 cell morphology as a decrease in cell spread area and perimeter was 
observed (Figure 3.3 and 3.9). The phenotypic morphology of cancer cells has been widely 
linked to their ability to migrate (Clark and Vignjevic, 2015). The shRNA and CRISPR PAK1 
knockdown cell lines also showed a reduction in 2D cell migration compared to WT and 
control cells (Figure 3.4 and 3.10). The shRNA and CRIPSR PAK1 knockdown cell’s 
morphological and 2D migration phenotypes are very comparable (Table 3.1 and 3.2) 
further demonstrating the importance of PAK1 in cell morphology and migration. 
Importantly the morphological and 2D migratory phenotypes were replicated on 
pharmacological inhibition of PAK1, by IPA-3, indicating the kinase activity of PAK1 is 
responsible for these phenotypes (Figures 3.10 and 3.11).   
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Next, the importance of PAK1 and its kinase activity was demonstrated in assays which 
offer greater physiological relevance. Depletion and pharmacological inhibition of PAK1 
resulted in a decrease in 3D cell invasion (Figures 4.1, 4.2 and 4.3) and in vivo cell 
migration (Figure 4.6 and 4.7). 
Employing an inducible PAK1 system to activate its kinase activity provided further 
evidence of the importance of PAK1 kinase activity in cell spreading, as PAK1 kinase 
activation caused an increase in cell spread area and perimeter (Figure 5.7 and 5.8). This 
change in cell size was associated with an increase in LIMK1/2 phosphorylation at 
threonine 508/505 (Figure 5.11). It is well established that LIMK activation at this site 
causes phosphorylation of cofilin to inhibit its actin severing activities allowing actin 
stabilisation and growth (Edwards et al., 1999, Arber et al., 1998, Yang et al., 1998). It is 
therefore thought that PAK1 induction of LIMK activity allows actin polymerisation causing 
lamellipodia formation and cell spreading/migration (Figure 6.1).  
A decrease in phosphorylation of CRKII at tyrosine 221 was observed on PAK1 activation 
(Figure 5.14). As PAK1 is a serine/threonine kinase this is not a direct event however PAK1 
could activate a phosphatase responsible for the decrease in phosphorylation levels at this 
site. As an increase in phosphorylation levels at this CRKII site is associated with membrane 
ruffling and cell migration (Takino et al., 2003, Abassi and Vuori, 2002) it is unlikely that 
PAK1 modulation of CRKII plays a specific role in the cell spreading phenotype observed. 
Multiple downstream pathways could be activated on PAK1 activation. CRKII could be part 
of alternative pathways which result in phenotypes other than cell spreading, which have 
not been studied here (Figure 6.1).  
PAK1 activation also induced an increase in the phosphorylation of FAK at serine 910 
(Figure 5.16). The phosphorylation of FAK serine 910 is potentially via the phosphorylation 
and activation of ERK3 at serine 189. This is hypothesised as ERK3 serine 189 
phosphorylation levels also increase on PAK1 activation (Figure 5.19). This serine site on 
ERK3 is a known downstream target of PAK1 (De la Mota-Peynado et al., 2011, Deleris et 
al., 2011), previous studies have demonstrated the ability of ERK proteins to 
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phosphorylate FAK at serine 910 (Li et al., 2010, Hunger-Glaser et al., 2004, Jiang et al., 
2007) and ERK3 is able to phosphorylate serine residues (Boulton et al., 1991). However, 
the serine/threonine kinase PAK1 could also phosphorylate the serine 910 site on FAK 
directly. Whilst it is not clear how this pathway could be directly coordinated to cell 
migration it is possible this is due to the continuous antagonistic relationship and cross 
talk between RhoA and Rac1/Cdc42 (Byrne et al., 2016). The tight spatial and temporal 
regulation between these Rho GTPases could also regulate this pathway by causing the 
activation of PAK1, as PAK1 is downstream major downstream effector of both Rac1 and 
Cdc42 (King et al., 2014).  
 
Interestingly, FAK serine 910 phosphorylation has previously been linked to cell spreading 
and migration. Zheng et al. (2009) have previously demonstrated that FAK serine 910 
phosphorylation recruits PIN1 and PTP-PEST which colocalise to the lamellipodia of 
migrating cells with FAK. PAK1 is involved in this pathway which causes the serine 910 
phosphorylation, resulting in the dephosphorylation of FAK at tyrosine 397 and an 
increase in cell migration (Zheng et al., 2009). A Rac1 induced signalling pathway has also 
been demonstrated to cause phosphorylation of FAK at serine 910, resulting in focal 
adhesion turnover during cell spreading (Flinder et al., 2011). This is another pathway that 
PAK1 could be implicated in as PAK1 is a direct downstream effector of Rac1 (Manser et 
al., 1994).  
Other studies have indicated a role for serine 910 phosphorylation of FAK and focal 
adhesion turnover. The FAT domain of FAK ensures its recruitment to focal adhesions via 
paxillin binding (Kadare et al., 2015). FAT domain opening is essential for focal adhesion 
turnover, and FAK mutants which facilitate FAT opening are capable of restoring focal 
adhesion turnover in FAK deficient cells (Kadare et al., 2015). These FAT domain opening 
mutants are associated with an increase in serine 910 phosphorylation therefore 
indicating this phosphorylation may play a role in focal adhesion turnover (Kadare et al., 
2015). It has previously been speculated that phosphorylation of FAK at serine 910 results 
in reduced binding between FAK and paxillin leading to adhesion turnover (Hunger-Glaser 
175 
 
et al., 2004). It is therefore hypothesised PAK1 induced phosphorylation of FAK at serine 
910 causes focal adhesion turnover and allows cell spreading associated with cell 
migration (Figure 6.1). The cell spreading observed on PAK1 activation in the inducible 
system would require rapid adhesion turnover. Similarly, adhesions turnover is also 
required during cell migration and therefore could explain why perturbation of PAK1 by 
knockdown and pharmacological inhibition causes a decrease 2D migration, 3D invasion 
and in vivo cell migration.    
In conclusion, this thesis demonstrated the importance of PAK1 in TNBC cell morphology 
which impacts migratory phenotypes. 2D migration, 3D invasion and in vivo cell migration 
were all impaired on the depletion of PAK1, highlighting its importance in TNBC cell 
migration. The role of PAK1 in cell spreading and migration was attributed to its kinase 
activity as pharmacological inhibition of the protein also resulted in the same 
morphological and migratory phenotypes. Finally, potential PAK1 downstream signalling 
pathways were identified which are shown in the proposed model (Figure 6.1).  
Future validation of this pathway is needed. Creating a cell line with depleted or complete 
knockout levels of ERK3 and FAK expression would serve as an invaluable tool to study this 
pathway further. 2D migration, 3D invasion and zebrafish xenograft assays could then be 
performed to identify the role of these proteins in breast cancer cell migration and 
invasion. Phenocopy of the results observed for PAK1 depleted studies in this thesis would 
be strongly indicate these proteins were part of the same pathway. Furthermore, further 
validation of the nature of the phosphorylation of FAK at serine 910 by PAK1, whether it 
be direct or indirect, would be beneficial to identify potentially novel therapeutic targets 
to combat cancer cell migration and metastasis that are in this pathway. This could be 
done by in vitro phosphorylation assays, interaction studies, inhibitor studies that target 
PAK1 and ERK3, and mutational studies which target key residues of PAK1 and ERK3 to 
determine the effects of FAK serine 910 phosphorylation. Once completed suitable 
therapeutic targets in this pathway could be identified, experiments with existing 
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inhibitors could be performed and novel drug design would allow further investigation 
into the validity of this pathway being targeted in a clinical setting.   
 
From new proteins involved in cell migration being identified, to feedback mechanisms 
between different signalling pathways being uncovered, the study of cancer cell migration, 
invasion and metastasis is a rapidly growing field. This project helps to identify and validify 
important regulators of cell migration and novel potential targets to combat metastasis. 
A new term coined ‘migrastatics’ refers to drugs that interfere with all modes of cancer 
cell migration and invasion (Gandalovicova et al., 2017). There is a growing belief within 
the field of cancer research that metastasis needs to be prevented and/or treated to cure 
a patient of their disease. With continuous research into cancer cell migration and 
invasion, the identification of novel therapeutic targets and development of anti-
metastatic drugs it is promising that migrastatics agents could soon enter clinical trials and 






Figure 6.1 A schematic diagram of PAK1 downstream signalling to promote cell spreading and 
migration. PAK1 can phosphorylate LIMK1/2 at threonine 508/505 which, due to its inhibitory 
effects on cofilin’s actin severing abilities can promote lamellipodia formation. PAK1 can also 
phosphorylate ERK3 at serine 189, this is thought to phosphorylate FAK at serine 910, however 
PAK1 could potentially phosphorylate FAK at serine 910 directly. Phosphorylation of FAK serine 
910 plays a role in focal adhesion turnover. Both lamellipodia formation and focal adhesion 
turnover are required for efficient cell spreading and migration. PAK1 kinase activation indirectly 
cause a decrease in phosphorylation of CRKII at tyrosine 221, however the mechanism by which it 
does so is not known. The decrease in CRKII tyrosine 221 phosphorylation is which is unlikely to 
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